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ABSTRACT 
Autism spectrum disorders (ASDs) are clinically characterized by decreased 
communication abilities, impaired social interaction, and the occurrence of 
repetitive behaviors, with high genetic heritability. Ubiquitin protein ligase E3A 
(UBE3A) is a gene located on human chromosome 15q11-13, a region that has 
been the focus of genetic studies of susceptibility to ASD AND Angelman 
syndrome. An increased UBE3A gene dosage and thus an elevated amount of 
E6AP, the protein product of UBE3A, is associated with ASD. However, the 
underlying cellular and molecular details remain poorly understood. Normal 
development of neuronal structure is critical for intercellular connectivity and 
overall brain function, and abnormal brain development is a commonality 
amongst ASDs. These studies therefore investigated the role of increased 
dosage of Ube3A/E6AP in dendritic arborization and synapse maturation during 
brain development. Increased E6AP expression in vitro led to significant 
reduction in dendritic arborization by thinning and fragmentation of the distal tip, 
along with a decrease in spine density and an increase in immature spines in 
hippocampal neurons. This morphological remodeling effect was mediated by the 
  vii 
ubiquitination and subsequent degradation of the X-linked inhibitor of apoptosis 
protein (XIAP) by E6AP, which led to activation of caspase-3. Furthermore, 
activated caspases cleaved tubulin, leading to retraction of microtubules from the 
distal tip of dendrites, dendritic thinning and eventual disappearance. In vivo 
studies investigated the role of E6AP in ASD-related neuronal development in 
Ube3A 2X transgenic mice and found that, consistent with our in vitro studies, 
increased E6AP in the brain lead to decreased XIAP levels, increased active 
caspase-3, and enhanced tubulin cleavage in hippocampal tissue in Ube3A 2X 
mice. In accord, Ube3A 2X mice showed a reduction in dendritic growth and 
branching and spine density. This work elucidated an important role of 
Ube3A/E6AP in dendritic pruning and identified XIAP as a novel ubiquitination 
target of E6AP. These findings provide a new insight into the molecular pathways 
underlying neurodevelopmental defects in Ube3A/E6AP-associated ASDs.  
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CHAPTER ONE: INTRODUCTION 
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1.1 Neurodevelopment and Autism spectrum disorders  
The human brain consists of trillions of connections, namely synapses, made by 
86 billion neurons (Azevedo et al., 2009). The proper development of all of these 
connections, therefore, is critical for normal brain function. The establishment of 
brain structure and cortical layers begins during prenatal neuronal development, 
when neurons produced in the ventricular zone migrate radially out into the 
developing neocortex to form six distinct layers (Huang, 2009). After initial 
migration, neurons undergo extensive morphological change to form specific 
synaptic connections with target neurons via axon formation and dendritic arbor 
elaboration. Synaptic formation and refinement occurs during prenatal and early 
postnatal periods in an activity-dependent manner, and brain circuitry can 
continue to be modified into adolescence and early adulthood. Disruption in any 
of these developmental processes can cause abnormalities in overall brain 
connectivity and lead to neurodevelopmental disorders.  
 Autism Spectrum Disorders (ASDs) are a heterogeneous class of 
neurodevelopmental disorders characterized by three main behavioral traits: 
impaired social interactions, lack of communication, and increased repetitive 
behaviors (Levy et al., 2009). However, these core clinical symptoms are often 
accompanied by other symptoms and disorders. Developmental comorbidities 
may include cognitive and intellectual disability, language deficits, attention 
problems and hyperactivity, motor delays, and hypotonia (Newschaffer et al., 
2007). Psychiatric and behavioral comorbidities include anxiety, depression, 
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obsessive-compulsive disorder, defiant and aggressive behavior, and self-
injurious behavior (Hartley et al., 2008; Simonoff et al., 2008). Other common 
comorbid features are seizures and epilepsy, gastrointestinal difficulties, and 
sleep disruption (Limoges et al., 2005; Nikolov et al., 2009; Rapin and Tuchman, 
2008).  
The genetic basis of ASDs is also extremely heterogeneous, as hundreds 
of different genes have been implicated in their cause. Several genes implicated 
in ASDs are part of a network of genes that regulate neuronal activity at the 
synapse and cause abnormalities in dendritic development, synaptic growth and 
plasticity, and neuronal connectivity. This class of genes includes FMR1, LIS1, 
MECP2, PTEN, SHANK1/2/3, TAOK2, TSC1/2, Neuroligins, Neurexins, 
KIAA2022/KIDLIA and UBE3A. Pathological studies of ASD patients have 
revealed neurodevelopmental defects such as abnormal brain growth, impaired 
neuron morphology and brain cytoarchitecture, along with impaired synapse 
formation (Chen et al., 2015). The vast genetic landscape of ASDs and the 
resulting variability in pathology and causative pathways have made studying 
and treating ASDs a great challenge.  
   
1.2 Ube3A/E6AP: an E3 ligase involved in Angelman syndrome and ASDs 
1.2.1 Genomic imprinting and regulation of UBE3A/E6AP  
One of the major genes implicated in ASDs is the Ubiquitin Protein Ligase E3A, 
UBE3A, the gene that encodes the E6-associated protein (E6AP), a protein that  
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Table 1.1 Genes associated with ASDs 
Neurodevelopmental 
Disorder 
Associated Gene Protein product 
Fragile X Syndrome (FXS), 
ASD 
FMR1 FMRP 
Rett Syndrome (RTT), ASD MECP2 MeCP2 
Phelan-McDermid syndrome, 
ASD 
SHANK1/2/3 Shank1, 2, 3 
Tuberous Sclerosis Complex, 
ASD 
TSC1, TSC2 Hamartin, tuberin 
ASD LIS1 Lissencephaly 1 
ASD NRXN1/2/3 Neurexin 1/2/3 
ASD TAOK2 TAOK2 
ASD PTEN PTEN 
ASD KIAA2022 KIDLIA 
Angelman syndrome and ASD UBE3A E6AP 
 
Table 1.1  
Summary of some genes associated with ASDs that regulate neuronal activity at 
the synapse and cause abnormalities in dendritic development, synaptic growth 
and plasticity, and neuronal connectivity.  
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is expressed in an imprinted manner in the brain. From here onwards, UBE3A 
will refer to the gene, and E6AP will refer to its protein product. Genomic 
imprinting marks the parental origin of chromosomal subregions and results in 
allele-specific differences in DNA methylation, transcription, and replication. 
Within the chromosome region 15q11-q13, the gene UBE3A is imprinted in the 
brain, resulting in maternal expression in human fetal brain and adult cortex 
(Rougeulle et al., 1997; Vu and Hoffman, 1997). Similar imprinting in UBE3A also 
exists in rats and mice (Albrecht et al., 1997).  Although the mechanism of tissue-
specific UBE3A imprinting is not fully understood, its expression in general has 
been found to be mediated by the presence of an antisense transcript that is 
paternally expressed, UBE3A-ATS (Rougeulle et al., 1998). UBE3A-ATS is a 
~460-kb noncoding RNA that initiates in the 15q11-q13 region of the paternal 
allele and overlaps UBE3A, silencing the paternal expression of the gene in the 
brain (Figure 1.1) (Runte et al., 2001). Similarly, the murine Ube3A-ATS is also 
observed to be paternal-specific and restricted to the brain (Chamberlain and 
Brannan, 2001).  
The UBE3A gene encodes three potential E6AP protein isoforms generated by 
differential splicing (Yamamoto et al., 1997). The coding region of E6AP is 
2,700bp long and consists of 10 exons, encoding for 865 amino acids 
(Huibregtse et al., 1993a). The three isoform are all of similar molecular weight, 
around 100 kDa, and are generally undistinguishable in size by SDS-PAGE. 
Isoforms 2 and 3 have an additional 20 and 23 amino acids, respectively, at their 
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amino-terminus. Importantly, the different isoforms do not affect the catalytic 
function of E6AP as an E3 ligase. However, it is unknown whether the variable 
amino terminus could account for differential ubiquitination substrate specificity 
by the three isoforms (Yamamoto et al., 1997). Interestingly, a more recent study 
reported that Ube3A isoform 1 RNA is encoded by a truncated sequence of the 
gene and does not include the E3 catalytic domain sequence (Valluy et al., 
2015). Furthermore, it is not detectably translated into protein, but its expression 
can be upregulated by neuronal activity and promote spine maturation in rat 
hippocampal neurons. It was suggested that Ube3A1 RNA might be a target 
RNA for microRNAs, providing a novel protein expression-independent function 
of Ube3A (Valluy et al., 2015).  
Neuronal activity can alter expression of E6AP (Greer et al., 2010). 
Specifically, expression of E6AP mRNA in cultured neurons is increased by 
either membrane depolarization or glutamate receptor activation, while blocking 
activity with NMDA receptor, sodium channel, or AMPA receptor inhibitors 
decreased E6AP mRNA expression. In addition, E6AP expression is induced in 
response to environmental stimuli that trigger experience-dependent synaptic 
development, as shown in mice that received an enriched environment compared 
to those in a standard cage. This increase was found to be regulated by the 
binding of the activity-regulated transcription factor myocyte enhancer factor 2  
(MEF2) to UBE3A promoters 1 and 3 (Greer et al., 2010). Interestingly, MEF2  
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Figure 1.1 UBE3A imprinting and E6AP structure 
 
 
(A) The UBE3A gene is located on chromosome 15 within the region of 15q11-
15q13. (B) Within the chromosome region 15q11-q13, the gene UBE3A is 
maternally imprinted in the brain. A paternally expressed antisense transcript 
(UBE3A-ATS) initiates in the 15q11-q13 region of the paternal allele and 
overlaps UBE3A, silencing the paternal expression of the gene in the brain. This 
imprinting results in expression solely from the maternal allele in the brain. (C) 
E6AP is an 862-amino acid protein with a C-terminal HECT E3 ligase domain. It 
also contains a binding site for the Human Papillomavirus Virus 16 (HPV16) 
protein E6 (E6 BS). The catalytic cysteine of E6AP is located at C820 (red).  
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has previously been shown to control synapse development and regulates a 
number of genes that have been implicated in ASDs (Flavell et al., 2006; Morrow 
et al., 2008). Further involvement of synaptic activity on the levels of E6AP was 
reported in another study (Filonova et al., 2014). Levels of nuclear and 
cytoplasmic E6AP were increased after neuronal depolarization in primary 
neuron culture, and upregulation of E6AP was observed in mice with a E6AP -
YFP reporter following fear conditioning. Additionally, lack of E6AP lead to 
deficits in the increased activity-dependent phosphorylation of the kinase 
ERK1/2, a process that is important in synaptic plasticity and memory formation 
(Filonova et al., 2014; Thomas and Huganir, 2004). These studies suggest that 
E6AP levels are regulated by synaptic activity and that loss of experience and 
activity-dependent induction of E6AP expression during postnatal development 
may contribute to ASDs. 
 
1.2.2 Gene dosage of UBE3A/E6AP  
Proper gene dosage of UBE3A is crucial to normal brain development, as 
evidenced by the neurodevelopmental disorders associated with deletions, 
mutations, and copy number variations of UBE3A. Angelman syndrome (AS) was 
characterized behaviorally by Harry Angelman to consist of “puppet”-like 
behavior, a distinctive feature of AS. AS manifests itself as severe developmental 
delay with a virtual absence of speech and abnormal gait (Williams et al., 1995). 
In addition, patients exhibit coordination difficulties, a contagiously happy 
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demeanor, prominent laughing, tongue protrusion, and a seizure disorder 
(Williams et al., 1995). Some characteristics of AS may be seen on the spectrum 
of autistic features, such as impaired use of nonverbal communication, absence 
of speech, attentional deficits, hyperactivity, feeding and sleeping problems, and 
delays of motor development (Williams et al., 2006a; Williams et al., 2001).  
AS is primarily caused by deletions and mutations in UBE3A, and its 
specific genetic causes are differentiated by five molecular classes (Clayton-
Smith and Laan, 2003; Lossie et al., 2001). Class I accounts for 65-70% of AS 
cases and is caused by a de novo deletion of the maternal chromosome 15q11-
q13, causing a loss of all E6AP expression in the brain (Clayton-Smith and Laan, 
2003). Class II patients have uniparental disomy (UPD) for chromosome 15 and 
therefore fail to inherit a maternal copy of UBE3A (Clayton-Smith and Laan, 
2003). Class III patients are those without deletions or UPD, but with abnormal 
methylation of the chromosome 15 maternal allele, resulting in a defect in 
maternal expression (Reis et al., 1994). Class IV patients are those who have 
mutations within UBE3A (Kishino et al., 1997; Matsuura et al., 1997). Point 
mutations in AS patients have been found throughout the entire coding region 
with clusters in exon 9, which contains the E6AP HECT domain. Many mutations, 
including frameshift, nonsense, and splice mutations, have been found to be 
located within the region encoding the catalytic cleft between the two lobes of the 
HECT domain (Cooper et al., 2004). Finally, Class V patients are designated as 
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those with a clinical phenotype of AS with no chromosome 15 abnormality 
(Lossie et al., 2001).  
A potential treatment for the imprinting defects in AS may be to unsilence 
the dormant paternal allele in neurons and restore E6AP expression despite the 
loss of maternal expression (Mabb et al., 2011). Indeed, an unbiased, high 
throughput screen in neurons from AS mice lead to the discovery of twelve 
topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the 
paternal UBE3A allele (Huang et al., 2011). One of the drugs found, topotecan, 
upregulated levels of active E6AP by downregulating the paternal UBE3A-ATS. 
Expression of the paternal UBE3A allele was unsilenced by topotecan in the 
hippocampus, neocortex, striatum, cerebellum, and spinal cord, suggesting that 
silencing the UBE3A-ATS and reactivating paternal expression of E6AP may 
serve as a potential therapeutic strategy for patients with AS (Huang et al., 
2011). Similarly, it has been shown that expression of a truncated Ube3A-ATS 
unsilenced paternal E6AP and was able to ameliorate behavioral deficits in AS 
mice (Meng et al., 2013).   
 ASDs, on the other hand, are caused by copy number variations (CNVs) 
in the UBE3A gene.  Individuals with an additional maternal copy of UBE3A 
(dup15) and those with two extra copies from an isodicentric extranumery 
chromosome (idic15) both display autism penetrance, with the two extra copies 
resulting in a more severe phenotype (Borgatti et al., 2001; Hogart et al., 2010). 
Consistent with the imprinted expression of UBE3A, ASDs arise from maternally, 
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but not paternally, derived 15q11-q13 duplications (Cook et al., 1997). These 
genetic studies suggest a role for UBE3A in neuronal development that is 
dependent on the expression dosage of the gene. 
 
1.2.3 E6AP structure and function  
E6AP was first discovered as the ubiquitin protein ligase involved in the 
degradation of the tumor repressor p53 (Scheffner et al., 1993).  Human 
papillomavirus type 16 (HPV16) viral infections are associated with malignant 
lesions leading to cervical cancer and encode the oncoprotein E6 (zur Hausen, 
1991). The E6 protein leads to degradation of the tumor repressor p53 in cells 
infected with HPV16, which was mediated by the involvement of a 100 kDa 
protein (Huibregtse et al., 1991). Indeed, that protein was termed E6-associated 
protein (E6AP) and was found to be a necessary component in the ubiquitination 
and degradation of p53 in cancer cells (Scheffner et al., 1993). The binding 
region for E6 is localized to the N-terminal of E6AP, from amino acid 391 to 408, 
while the p53 binding domain consists of 500 amino acids. Additionally, the last 
84 amino acids of E6AP were required for p53 degradation (Huibregtse et al., 
1993b). The COOH-terminal 350 amino acids of E6AP comprise the HECT 
(homology to E6AP C-terminus) domain, a region shared by several E3 ligases 
structurally similar to E6AP, and this domain is required for the ubiquitination 
function of E6AP (Huibregtse et al., 1995; Huibregtse et al., 1993a) (Figure 
1.1C). Furthermore, the catalytic active site of E6AP is localized to a cysteine at 
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position 833, as mutating this cysteine to alanine renders the E3 ligase unable to 
form a thioester bond with ubiquitin (Scheffner et al., 1995). E6AP can also self-
ubiquitinate in HPV16-positive cells and mediate its own degradation (Kao et al., 
2000). This requires the binding of E6 to E6AP and is mediated by the 
intramolecular transfer of ubiquitin from the active cysteine site of E6AP to one of 
its own lysine residues, possibly acting as a multimer in order to achieve self-
ubiquitination (Kao et al., 2000).  
 Crystal structure of E6AP showed that the HECT domain consists of two 
lobes that pack loosely across a small interface and are connected by a three-
residue hinge (residues 738 to 740). The larger NH2-terminal lobe of the HECT 
domain (residues 495 to 737) has a mostly α-helical structure, while the smaller 
COOH-terminal lobe (residues 741 to 852) has an α/β structure and contains the 
catalytic Cys820 (Huang et al., 1999). Notably, many E6AP mutations in AS 
patients are located in the HECT domain and around the catalytic site (Cooper et 
al., 2004; Nawaz et al., 1999). Several AS mutations that affect E6AP substrate 
ubiquitination inhibit the E3 ligase from forming a thioester bond with ubiquitin 
(Cooper et al., 2004). In addition, an autism-linked missense mutation disrupts 
E6AP phosphorylation by protein kinase A (PKA) at residue T485 and leads to an 
enhancement of its activity towards other substrates (Yi et al., 2015). Thus, there 
is a strong link between the E3 ligase function of E6AP and its involvement in 
neurodevelopmental disorders, suggesting that E3 ligase function is essential to 
the role of E6AP in normal brain development.  
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Another function of E6AP has been discovered as coactivator for the 
nuclear hormone receptor superfamily. Nuclear hormone receptors are ligand-
induced transcription factors that require coactivators to achieve optimal function 
(Shibata et al., 1997). Coactivators enhance receptor function by acting as a 
bridge between DNA-bound receptors and basal transcription factors (Chen et 
al., 1997). E6AP contains a nuclear localization signal that allows it to be 
localized to the nucleus, and three LXXL motifs, which are important for receptor 
interaction (Hatakeyama et al., 1997; Heery et al., 1997). E6AP was found to 
interact with the liganded form of the progesterone receptor and increase its 
transcriptional activity (Nawaz et al., 1999). Interestingly, its function as a 
receptor coactivator is independent from its function as a ubiquitin protein ligase. 
However, the coactivation function is not associated with the phenotypic 
manifestation of AS, and so far no evidence has supported the role of receptor 
activation of E6AP in neuronal processes, indicating that AS is primarily caused 
by defects in the E3 ligase function of E6AP.  
 
1.2.4 E3 ligases and the ubiquitin-proteasome pathway  
The proteolysis of specific substrates via the ubiquitin-proteasome pathway 
(UPS) is essential to neuronal development and synaptic plasticity (Hegde and 
DiAntonio, 2002). Proteasome-mediated degradation of proteins involves the 
addition of ubiquitin to specific target molecules followed by their trafficking to the 
proteasome for degradation into small peptides and amino acids. This process 
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occurs via coordinated actions of three classes of enzymes: E1, E2, and E3. The 
ubiquitin-activating enzyme E1, activates the free ubiquitin in an ATP-dependent 
manner. The conjugating enzyme E2 then carries the transfer of the activated 
ubiquitin, and a substrate-specific E3 ligase attaches the ubiquitin molecule to a 
target protein (Figure 1.2). Attachment of a single ubiquitin molecule to a target 
protein (monoubiquitination) usually signals a conformational change in the 
protein, whereas attachment of single ubiquitin molecules to multiple lysine 
residues of a target protein at the membrane marks it for endocytosis. Once a 
ubiquitin molecule has attached to a protein, another ubiquitin can be attached to 
an internal lysine residue of the first ubiquitin, and this can go on to form a 
polyubiquitin chain on the target protein. Polyubiquitination tags a protein 
substrate for degradation and causes it to be trafficked to the 26S proteasome 
(Figure 1.2) (Hegde, 2004). Ubiquitin proteasome-mediated degradation can also 
be regulated by the removal of ubiquitin by deubiquitinating enzymes (DUBs) 
(Glickman and Ciechanover, 2002). DUBs can reverse the ubiquitination of a 
protein, or disassemble the polyubiquitin chains before the ubiquitinated proteins 
enter the proteasome. Through their actions, DUBs can also regulate receptor 
endocytosis and trafficking (McCann et al., 2016). At the synapse, ubiquitination 
can modulate neurotransmitter receptors, as well as components of the 
postsynaptic density (Ehlers, 2003). The UPS also plays an important role in cell 
growth, neurite extension, structural remodeling, and synaptic formation and 
plasticity (d'Azzo et al., 2005; Hurley et al., 2006; Nandi et al., 2006; Segref and 
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Hoppe, 2009; Shearwin-Whyatt et al., 2006). Impairments in ubiquitin-mediated 
protein degradation can therefore lead to deficits in neuronal development and 
the maintenance of synaptic connections.  
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Figure 1.2 E3 ligases and the ubiquitin proteasome system 
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Figure 1.2 E3 ligases and the ubiquitin proteasome system 
Proteasome-mediated degradation of proteins involves the addition of ubiquitin to 
specific target molecules followed by their trafficking to the proteasome for 
degradation into small peptides and amino acids. This process occurs via 
coordinated actions of three classes of enzymes: E1, E2, and E3. The ubiquitin-
activating enzyme E1, activates the free ubiquitin in an ATP-dependent manner. 
The conjugating enzyme E2 then carries the transfer of the activated ubiquitin, 
and a substrate-specific E3 ligase attaches the ubiquitin molecule to a target 
protein. Once a ubiquitin molecule has attached to a protein, another ubiquitin 
can be attached to an internal lysine residue of the first ubiquitin, and this can go 
on to form a polyubiquitin chain on the target protein. Polyubiquitination tags a 
protein substrate for degradation and causes it to be trafficked to the 26S 
proteasome. 
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1.2.5 Ubiquitination Targets of Ube3A/E6AP 
As the primary function of E6AP is that of an E3 ligase and its function is 
mediated via protein ubiquitination, it is critical to identify its downstream targets. 
To date, several E6AP ubiquitination targets have been identified, including the 
tumor suppressor p53, the PDZ-containing protein Scribble, the transcriptional 
repressor NFX1-91, the DNA-repair protein HHR23A, the AMPA receptor-
trafficking regulator Arc, the RhoA guanine nucleotide exchange factor Ephexin5, 
and the small-conductance potassium channel SK2. Below is a discussion of 
some of these major E6AP targets.  
1.2.5.1 The tumor repressor P53 
The tumor repressor p53 was one of the first ubiquitination targets discovered for 
E6AP in the context of viral infection by HPV16. Although most of the studies on 
the interaction between E6AP and p53 have focused on its role in cancer, p53 
has also been studied in the context of AS. In mice maternally deficient for E6AP, 
increased cytoplasmic p53 was found in Purkinje and hippocampal cells 
compared to wild type mice (Jiang et al., 1998). No differences in p53 transcripts 
were found between the mice, suggesting that the change in p53 levels was due 
to a posttranscriptional effect. In addition, increased p53 immunoreactivity was 
found in Purkinje cells of a patient with clinical diagnosis of AS, suggesting that 
E6AP can regulate levels of p53 in the absence of the E6 viral protein (Jiang et 
al., 1998). Although these UBE3Am-/p+ mice display impaired contextual learning 
and hippocampal LTP, it is unclear whether the changes in p53 contribute to the 
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behavioral phenotype of AS mice. Furthermore, how the ubiquitination of p53 by 
E6AP affects neuronal developmental or morphology in the context of AS or ASD 
remains to be studied.  
 
1.2.5.2 The human homolog of the yeast DNA report protein Rad 23 
HHR23A 
One of the substrates identified with the normal cellular function of E6AP, as 
opposed to its role in cancer cells, is HHR23A, the human homolog of the yeast 
DNA repair protein Rad23 (Kumar et al., 1999). HHR23A levels are increased in 
response to DNA damage, and its levels are also regulated in a cell-cycle 
dependent manner, with specific degradation occurring during the S phase. 
HHR23A binds E6AP and is ubiquitinated in vitro in a cell-cycle and E6AP-
dependent manner, which is enhanced with the overexpression of wild-type 
E6AP, but not the E3 ligase mutant E6AP C833A (Kumar et al., 1999). Although 
this study provides important information on the cellular function of E6AP in DNA 
repair and cell cycle progression via regulation of HHR23A levels, the role of this 
ubiquitination target has not been studied in the context of AS and ASD. 
However, the E6AP field has utilized HHR23A as a tool to search for proteins 
that have similar sequences and binding sites and may therefore be additional 
E6AP targets (Greer et al., 2010; Kuhnle et al., 2013).  
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1.2.5.3 The synaptic protein Arc 
One of the major findings in the field of AS and UBE3A/E6AP was the discovery 
of the synaptic protein Arc as a target for E6AP-mediated ubiquitination (Greer et 
al., 2010). Arc regulates the trafficking of AMPARs at the synapse by 
accelerating endocytosis and reducing surface expression (Chowdhury et al., 
2006). In mouse brain extracts from wild-type mice, E6AP and Arc interact and 
Arc ubiquitination was increased, along with decreased Arc protein levels. 
Increased expression of E6AP, but not the E3 ligase mutant E6AP C833A, lead 
to increased Arc ubiquitination, which was blocked by the proteasome inhibitor 
MG132. Under the conditions of increased neuronal activity, either by kainic acid 
or an enriched environment, Ube3Am-/p+ mice have higher levels of Arc than wild-
type animals. Neurons transfected with E6AP shRNA have reduced levels of the 
AMPAR subunit GluA1, which was caused by increased endocytosis of GluA1 
and resulted in decreased miniature excitatory postsynaptic currents (mEPSCs). 
The reduction in GluA1 was mediated by E6AP -dependent ubiquitination of Arc, 
and Ube3Am-/p+ mice also had decreased levels of AMPARs (Greer et al., 2010). 
Further supporting this work was the finding that seizure-like activity in the AS 
mouse model could be attenuated by reducing Arc expression (Mandel-Brehm et 
al., 2015). However, the ubiquitination-dependent degradation of Arc by E6AP 
has been challenged. Another study demonstrated that no interaction was found 
between full-length Arc and E6AP, and that increased E6AP expression had no 
effect on Arc levels or Arc ubiquitination (Kuhnle et al., 2013). Furthermore, they 
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showed that down-regulation of E6AP expression stimulates estradiol-induced 
transcription of the Arc gene, suggesting that Arc protein levels are controlled by 
E6AP at the transcriptional rather than post-translational level (Kuhnle et al., 
2013).  
1.2.5.4 The RhoA guanine nucleaotide exchange factor Ephexin5 
EphB receptors are expressed on developing axons and dendrites and regulate 
actin cytoskeleton remodeling critical for excitatory synapse development via 
binding to their ligand EphrinBs and the subsequent activation of guanine 
nucleotide exchange factors (GEFs) (Klein, 2009). Activation of EphBs in 
hippocampal neurons leads to an increase in dendritic spines and functional 
excitatory synapses, whereas disruption of EphB function leads to defects in 
spine morphogenesis and a decrease in excitatory synapse number (Ethell et al., 
2001; Henkemeyer et al., 2003; Kayser et al., 2006; Penzes et al., 2003). 
Ephexin5, a RhoA GEF expressed in the brain, negatively regulates excitatory 
synapse development until EphrinB binding to the EphB receptor tyrosine kinase 
triggers Ephexin5 (E5) phosphorylation, ubiquitination, and degradation. The 
degradation of E5 promotes EphB-dependent excitatory synapse development 
and was found to be mediated by E6AP (Margolis et al., 2010). A Ube3A binding 
domain (UBD) sequence, corresponding to the E6AP-binding sequence of 
HHR23A, was identified in Ephexin5. Furthermore, immunoprecipitation showed 
binding between E6AP and E5. E5 levels were decreased in the presence of 
E6AP, but not the E3 ligase mutant E6AP C833A, and E5 degradation was 
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attenuated by shRNA-mediated knockdown of E6AP (Margolis et al., 2010). 
Additionally, E5 levels in the brains of Ube3Am-/p+ mice were significantly higher 
and E5 ubiquitination levels were reduced, supporting the role of E6AP in 
mediating E5 degradation by ubiquitination and potentially regulating excitatory 
synapse formation (Margolis et al., 2010).  
1.2.5.5 Small-conductance potassium channel 2 (SK2) 
Small-conductance potassium channels (SKs) are involved in synaptic 
transmission by contributing to the hyperpolarization after an action potential or 
repolarization after EPSCs (Adelman et al., 2012). In hippocampal neurons, 
synaptic SK channels become active upon NMDAR activation, leading to 
membrane repolarization and thus suppression of the NMDAR activity, a function 
that is important in regulating neuronal excitability for long-term potentiation 
(LTP), a well-studied form of synaptic plasticity important for learning and 
memory (Hammond et al., 2006; Ngo-Anh et al., 2005). In turn, LTP induction 
regulates levels of synaptic SK2 by triggering endocytosis (Lin et al., 2008). 
Recently, it was discovered that E6AP ubiquitinates SK2 and facilitates its 
internalization (Sun et al., 2015). Specifically, ubiquitination by E6AP was found 
to occur at the C-terminal K506/K514/K550 residues of SK2. Furthermore, 
synaptic SK2 levels were increased in the hippocampus of Ube3Am-/p+ mice, 
along with decreased ubiquitination of SK2. This resulted in impaired synaptic 
plasticity and decreased NMDAR function, suggesting that E6AP can modulate 
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synaptic plasticity by regulating SK2 channel levels via ubiquitination and 
endocytosis (Sun et al., 2015).  
1.2.6 Brain and cellular distribution of E6AP  
Knowledge of the imprinting and expression pattern of E6AP in the brain has 
come from studying various brain regions and tissues in the maternally-deficient 
Ube3Am-/p+ mice. It has been shown that maternal E6AP is expressed in the 
hippocampus, hypothalamus, olfactory bulb, cerebral cortex, striatum, midbrain, 
and cerebellum (Gustin et al., 2010). Expression is seen primarily in neurons, 
both excitatory and inhibitory neurons (Gustin et al., 2010). Within neurons, 
E6AP is enriched in the nucleus and dendrites in mouse brain tissue (Dindot et 
al., 2008). In cultured hippocampal neurons, E6AP also localizes to the nucleus 
and to presynaptic and postsynaptic compartments (Dindot et al., 2008).  
The expression of imprinted E6AP in the brain also seems to be 
temporally regulated. To study imprinting and the resulting expression, mouse 
models lacking either the paternal or maternal copy of UBE3A have been utilized 
(UBE3Am+/-p- or UBE3Am-/p+). In the visual cortex, low levels of expression of 
paternal E6AP remain during early postnatal development at postnatal day 6 
(P6), indicating that the paternal allele is not completely silenced at this stage 
(Sato and Stryker, 2010). Conversely, expression of E6AP at later developmental 
time points, around P27-P29, stem primarily from the maternal allele expression 
(Sato and Stryker, 2010). Although paternal E6AP expression becomes 
undetectable in neurons beyond the first postnatal week in mice, maternal E6AP 
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is expressed throughout postnatal development and into adulthood (Judson et 
al., 2014). However, this imprinting may not occur similarly throughout the brain. 
Although cortical lysates show residual expression of E6AP in Ube3Am-/p+ mice at 
birth that is diminished by adulthood, presumably from expression of the paternal 
allele, sub-cortical and cerebellar tissue express levels of E6AP at birth that are 
comparable to those in adult mice (Grier et al., 2015). Late-onset silencing of 
paternal Ube3A has also been observed in induced pluripotent stem cells 
(iPSCs) derived from an AS patient (Stanurova et al., 2016). These findings 
suggest that in AS mice and AS patients, normal development of neurons may 
occur while paternal E6AP expression remains, but developmental deficits begin 
to arise as paternal expression diminishes and the lack of maternal expression 
leads to a complete loss of E6AP function in the brain. The timing of this 
imprinting pattern suggests that deficits in AS may occur during a postnatal 
critical period of experience-dependent neuronal development.  
1.2.7 Animal models of Angelman syndrome and UBE3A-dependent ASD 
The UBE3A maternal deficient mouse model of AS (Ube3Am-/p+), in which a 
deletion mutation in exon 2 of UBE3A inhibits maternal expression of the gene, 
successfully captures many of the classical features associated with AS and is 
the most widely used AS mouse model (Jiang et al., 1998). Ube3Am-/p+ mice 
exhibit reduced brain weight, ataxia, motor impairments, abnormal EEG, and 
audiogenic seizures. These mice also display context-dependent learning and 
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memory impairments, and deficits in hippocampal long-term potentiation (Jiang 
et al., 1998).  
 Increased gene dosage of UBE3A has been modeled in mice to mimic the 
UBE3A CNVs in ASDs. The Ube3A 2X transgenic (Tg) mouse model exhibits a 
tripling of the normal Ube3A gene dosage in neurons, replicating idic15 in 
patients with autism (Smith et al., 2011). Ube3A 2X Tg mice show typical autistic 
behavioral deficits, including impaired social behavior, as measured by social 
preference tests, decreased communication, measured by vocalizations, and 
increased repetitive behavior, shown by excessive grooming. In addition, 
recordings in hippocampal slices showed reduced strength in excitatory synaptic 
transmission, both in frequency and amplitude, suggesting that E6AP may 
regulate glutamate transmission at both pre- and post-synaptic sites (Smith et al., 
2011).  
 
1.3 Dendritic growth and remodeling during neuronal development 
1.3.1 Dendrite formation and stability  
Dendrites are the main structures that receive information and integrate signals 
before the initiation of an action potential in neurons. Both the complexity of 
dendrites and the number of synaptic spines determine neuronal connectivity and 
communication. Development, refinement, and maintenance of the neuronal 
dendritic arbors are therefore crucial to normal brain function. The formation of 
dendritic arborization is a dynamic process. Models that have helped the field 
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understand dendrite development and the factors that regulate this process 
include the Xenopus tadpole, whose transparency at early stages of larval 
development allow for imaging in the intact animal, and Drosophila 
melanogaster, in which class IV dendritic arborization (da) neurons undergo 
extensive remodeling during metamorphosis (Cline, 2001; Yaniv and Schuldiner, 
2016).  
In the proliferative zone of the optic tectum of the Xenopus tadpole, 
recently differentiated neurons typically extend an axon first, and begin to 
elaborate a dendritic arbor several hours later. During the first few days of 
dendritic growth, arbors grow rapidly, so much that branch addition and retraction 
are happening on the time scale of 10-30 minutes and cells are barely 
recognizable from one day to the next, but this growth slows down to half its rate 
after several days and the structure of the arbor changes less (Wu et al., 1999). 
Several factors may play a role in regulating dendritic arbor growth in this model. 
One factor is synaptic input, where glutamatergic retinotectal synaptic inputs 
could influence the morphological development of tectal cells dendritic arbors 
(Wu et al., 1996). Indeed, the growth rate of optic tectal neurons is reduced by 
the NMDAR antagonists APV or MK801, but not by AMPAR antagonists, 
suggesting that dendritic arbor elaboration occurs in an NMDAR-dependent 
manner and that synaptic activity regulates dendrite formation (Rajan and Cline, 
1998). Furthermore, disruption of the NMDAR1 receptor gene in the mouse 
cortex prevents the formation of barrel in the somatosensory cortex, which 
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requires the development of oriented cortical neuronal arbors (Greenough and 
Chang, 1988; Iwasato et al., 2000). The deceleration of arbor growth is regulated 
by levels of the calcium/calmodulin-dependent kinase II (CaMKII), as suggested 
by the increase of CaMKII expression during the phase of slower dendritic arbor 
growth rate (Wu and Cline, 1998). Premature expression of CaMKII causes 
arbors to slow their growth rate, while blocking endogenous CaMKII maintains 
neurons in their rapid growth phase (Wu and Cline, 1998).  
In mammals, several factors affect dendritic growth and stabilization 
during development. Neurotrophic factors, such as nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), and neurotrophin-3 and -4 (NT-3 and 
NT-4, respectively) play a role in regulating dendrite growth and branching in 
cortical neurons by binding to the Trk family of tyrosine kinase receptors (Huang 
and Reichardt, 2001). Neurotrophins increase total dendritic length, the number 
of branch points in neuron morphology, and the number of primary dendrites, 
although which neurons they act on is specific for each neurotrophin. For 
example, layer 4 neurons in the cortex increase dendritic complexity in response 
to NT-3 and BDNF, while layer 5 and 6 change in response to NT-4 (Baker et al., 
1998; McAllister et al., 1995). These changes are mediated by the downstream 
effects of Trk receptors, mainly MAP kinase and PI-3Kinase (Posern et al., 
2000). These signaling pathways can regulate the activity of the Rho family 
GTPases, which can mediate actin cytoskeleton dynamics and induce dendritic 
remodeling (Yasui et al., 2001). In addition, specific mRNAs for cytoskeletal 
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proteins are present in dendrites, which can be upregulated by local protein 
synthesis mediated by BDNF (Aakalu et al., 2001). Notch1, a cell-surface 
receptor that is cleaved upon activation and can increase gene transcription, also 
plays a role in dendritic patterning (Weinmaster, 2000). Increased activity of 
Notch1 in hippocampal neurons leads to an inhibition of neurite outgrowth, 
whereas inhibiting Notch1 activation increases total neurite length (Berezovska et 
al., 1999; Sestan et al., 1999). Although Notch1 negatively regulates dendrite 
growth, it has a positive effect on dendrite branching, suggesting a complex role 
for Notch in dendritic development (Redmond et al., 2000).  
 In addition to dendrite development, dendrite stability is regulated by 
several key factors, mainly via the stabilization of the microtubule network. 
Microtubule components are key in maintaining dendrite structure, as cargo 
transport is important in replenishing the molecular components of dendrites, and 
disruptions in microtubule-based cargo trafficking can negatively affect dendrite 
stability. Disruptions in microtubule orientation can change local dendritic 
architecture and has been found to occur in some neurodevelopmental disorders 
(Purpura et al., 1982). Mutations in dynein and kinesin, the motors involved in 
carrying cargo up and down microtubules, can disrupt trafficking and decrease 
dendritic arbor formation and stabilization (Satoh et al., 2008). Importantly, Golgi 
outposts, which serve as local sites for protein trafficking, are localized at 
dendritic branch points and rely on microtubule motors for proper localization 
(Ori-McKenney et al., 2012). BDNF signaling is also involved in dendrite 
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stabilization, as shown by the induction of expression of microtubule-stabilizing 
proteins MAP1A and MAP2 in response to BDNF application (Koleske, 2013).  
Interestingly, dendritic spine maintenance is essential for dendrite stability. 
Reduced synaptic activity can lead to dendrite loss, and activity-dependent 
signaling synaptic molecules CaMKII and MEK can induce dendrite stabilization 
in cultured neurons (Vaillant et al., 2002). Although the precise mechanism by 
which this occurs is not yet known, it is possible that CaMKII can relocalize from 
dendritic spines to dendritic shafts upon stimulation, and potentially alter 
cytoskeletal proteins in dendrites (Lemieux et al., 2012). 
1.3.2 Dendritic pruning  
Following early developmental growth, mature branching patterns are 
established not only by simple neurite elongation and new branch formation, but 
also by branch retraction and elimination, where a portion of dendritic branches 
are shortened or removed by dendrite pruning in order to optimize the 
connectivity and function of neural circuits (Cline, 2001; Kozlowski and Schallert, 
1998). Dendritic pruning is a general developmental process occurring in 
neurons from insects to mammals (Parrish et al., 2007; Zehr et al., 2006).  
Much has been learned from the developmental dendritic pruning of class 
IV Drosophila dendritic arborization (da) sensory neurons. During 
metamorphosis, larval neurons undergo extensive pruning and regrowth, as 
larval-specific branches are replaced with adult-specific branches by remodeling.  
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Live imaging of dendrites undergoing pruning show that severing of branches is 
initiated by a localized degeneration of microtubules and thinning of the dendritic 
branch, followed by severing and fragmentation of the branch (Williams and 
Truman, 2005). This process is mediated by the microtubule-severing protein 
Katanin 60 (Lee et al., 2009). In addition, peripheral glial cells that wrap the 
dendrites of da neurons regulate the location of initial dendrite severing (Han et 
al., 2011). Following severing, detached dendrites undergo rapid fragmentation 
and clearance of the debris is carried out by phagocytes surrounding the neuron 
(Han et al., 2014; Williams and Truman, 2005).  
 The ubiquitin-proteasome system (UPS) regulates dendritic pruning in da 
neurons, as inhibiting UPS function blocks dendrite pruning (Kuo et al., 2005). 
The Drosophila E2 enzyme UbcD1 is required for the proteasome-mediated 
degradation of DIAP1, a caspase-antagonizing E3 ligase (Kuo et al., 2006). 
Degradation of DIAP1 subsequently results in local activation of caspases; 
specifically, the caspase Dronc is activated and promotes local pruning (Kuo et 
al., 2006; Williams et al., 2006b). Interestingly, compartmentalized calcium 
transients have been observed in specific branches before pruning and 
elimination, which can be inhibited by mutating the voltage-gated calcium 
channels (VGCCs), resulting in impaired dendritic pruning (Kanamori et al., 
2013). These calcium transients activate calpain proteases to promote pruning. 
However, calcium transients were not found to affect caspase activation, 
suggesting that calcium-mediated and caspase-mediated pathways work 
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independently yet cooperatively to induce pruning of specific dendrites (Kanamori 
et al., 2013).  
Mammalian dendritic remodeling has been studied in the sensory cortices 
of rats and mice.  In rats, remodeling has been studied in the olfactory bulb. 
Mitral cells are the output neurons of the olfactory bulbs and are major recipients 
of sensory input from the periphery. Mitral cell differentiation consists of 
overproduction of dendrites, selection of one primary apical dendrite, elimination 
of extra processes, and growth of secondary dendrites in response to sensory 
input (Malun and Brunjes, 1996). In the rat neocortex, selective and active 
elimination of dendrites after initial cortical layer establishment occurs in a neuron 
class-specific manner and is essential in shaping the functional architecture of 
the cortex (Koester and O'Leary, 1992). The cat visual cortex, dendrites of retinal 
ganglion cells (RGCs) are initially diffusely distributed, but over time with 
maturation, they lose their dendrites and remodel their arborization to either “ON” 
or “OFF” sublamina (Nelson et al., 1978). This remodeling is dependent on 
excitatory neuronal activity input, as RGCs do not undergo dendritic 
rearrangement if neuronal activity is blocked (Bodnarenko et al., 1995). Changes 
in dendritic branching in response to sensory activity are mediated by 
postsynaptic NMDARs; it was shown that in mice lacking the NMDAR NR1 
subunit in the cortex, dendritic remodeling of layer IV neurons fails to occur 
(Datwani et al., 2002).  
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 Recently, live two-photon imaging of adult mouse dentate granule cells 
(DGCs) demonstrated that dendritic pruning occurs over the course of 30 days 
after the neurons are born (Goncalves et al., 2016). Specifically, dendrites were 
shown to undergo overgrowth followed by pruning. It was hypothesized that 
dendrites undergo overgrowth in response cell-extrinsic factors, such as activity 
and extracellular cues, and that branch pruning occurs in a homeostatic manner 
regulated by cell-intrinsic factors (Goncalves et al., 2016).  
1.3.3 The role of E6AP in synaptic plasticity  
The signs and symptoms of ASDs often appear before three years of life, while 
social, emotional, and cognitive skills are developing (Walsh et al., 2008). This 
period correlates with a development phase of brain architecture, including the 
generation of new neurons, dendritic growth, synaptogenesis, neuron circuit 
formation, and experience-dependent remodeling (Fox et al., 2010).  
Several studies have implicated the role of E6AP in experience-dependent 
neuronal maturation. Ube3Am-/p+ mice were shown to have impaired experience-
dependent synaptic plasticity in the visual cortex (Yashiro et al., 2009). 
Specifically Ube3Am-/p+ do not exhibit ocular dominance plasticity induced by 
monocular deprivation, and visual cortex neurons show decreased mEPSCs in 
response to visual experience (Yashiro et al., 2009). Cortical circuitry and 
retinotopic maps form normally, with no obvious defects seen in cell density and 
overall cortical development in the visual cortex. However, spine density in the 
basal dendrites of the Layer V visual cortex neurons is reduced in Ube3Am-/p+ 
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mice (Sato and Stryker, 2010). The time for ocular dominance formation 
represents a critical period for experience-dependent visual cortex maturation, 
and UBE3A maternal allele expression is increased during this critical period, 
suggesting that E6AP plays a role in postnatal experience-dependent neuronal 
development (Sato and Stryker, 2010). Interestingly, in Ube3Am-/p+ mice, 
reinstatement of E6AP expression at birth and at 3 weeks of age was able to 
rescue motor deficits, while reinstatement in adults failed to show rescue effects, 
suggesting a specific time window during development when E6AP influences 
neuronal development (Silva-Santos et al., 2015). 
The role of E6AP has also been implicated in LTP. In the hippocampus of 
Ube3Am-/p+ mice, increased levels of inhibitory phosphorylation at Thr305 of 
CaMKII were found, thereby decreasing the activity of the protein, which is 
important in the induction of LTP (Lisman et al., 2012; Weeber et al., 2003). This 
change in CaMKII function was thought to be responsible for some of the 
learning impairments in Ube3Am-/p+ mice, as the behavioral and learning deficits 
were reversed when a mutation was introduced to block the inhibitory 
phosphorylation of CaMKII (van Woerden et al., 2007). E6AP was also shown to 
modulate NMDAR-mediated synaptic plasticity by ubiquitinating and internalizing 
SK2 channels (Sun et al., 2015).  
1.3.4 UBE3A/E6AP in neuronal development  
The role of E6AP has been implicated in neuronal development and 
morphological impairments in a growing number of studies. Alterations in E6AP 
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levels have lead to changes in dendritic and spine morphology. Ube3Am-/p+ AS 
mice have dendritic spines with inconsistent morphology, including variability in 
spine neck length and head size (Dindot et al., 2008). Hippocampal dendritic 
spines were lower in density and shorter in length in Ube3Am-/p+ mice than in 
wild-type (WT) mice (Dindot et al., 2008). When E6AP was downregulated in 
mice via in utero electroporation of shRNA, changes in the polarity of dendrites 
was observed (Miao et al., 2013). Specifically, at P7, the orientation property of 
the apical dendrite relative to the line perpendicular to the pial surface in layer 2/3 
neurons was impaired in neurons with E6AP shRNA. The length of the apical 
dendrite was also reduced compared to control neurons, both in cortical and 
hippocampal neurons. These deficits were attributed to the regulation of Golgi 
apparatus distribution; control neurons had Golgi enriched within the apical 
dendrite, whereas E6AP shRNA-transfected neurons had Golgi clustered near 
the nucleus. Interestingly, these deficits were rescued by the overexpression of 
shRNA-resistant E6AP isoform 2, the primary E6AP isoform expressed in the 
brain from embryonic to adult stages in mice (Miao et al., 2013). Furthermore, 
stunted apical dendrites and decreased dendritic polarity were observed in 
Ube3Am-/p+ mice (Miao et al., 2013). Supporting the role for Golgi dysfunction in 
AS, another study reported structural disruption of cisternal swelling of the Golgi 
apparatus in Ube3Am-/p+ cortical neurons (Condon et al., 2013). Gogli were found 
to be severely under-acidified, leading to osmotic swelling, and resulting in a 
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marked reduction in protein sialylation, a process dependent on Golgi pH 
(Condon et al., 2013).  
 Morphological deficits have also been found in Drosophila with a loss of 
dUBE3A, the homologue for Ube3A/E6AP. In the absence of dUBE3A, the 
number of terminal dendritic branches in class IV da sensory neurons was 
reduced (Lu et al., 2009). Da neurons in dUBE3A-null neurons fail to completely 
prune their dendrites during early metamorphosis, suggesting a pruning defect. 
Strikingly, overexpression of dUBE3A in da neurons decreased dendritic 
branching, implicating an important role for the dosage of E6AP in neuronal 
development (Lu et al., 2009).  
 During polarization of neurons, axons and dendrites require coordination 
of cellular energy to transport molecules and support axon and dendrite growth 
(Amato et al., 2011; Amato and Man, 2011). Impairments in energy supply could 
therefore be detrimental to neuron morphogenesis. Indeed, mitochondrial 
dysfunction has been observed in CA1 hippocampal neurons of AS mice (Su et 
al., 2011). Mitochondria exhibit abnormal morphology and a partial oxidative 
phosphorylation defect in the hippocampus and cerebellum (Su et al., 2011). 
Interestingly, supplementation with the coenzyme CoQ10 restores mitochondrial 
function and corrects motor coordination deficits and increased anxiety in these 
mice (Llewellyn et al., 2015).  
Loss of E6AP also leads to an excitatory/inhibitory imbalance in the brains 
of Ube3Am-/p+ mice that may contribute to seizure susceptibility in AS (Wallace et 
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al., 2012). Inhibitory GABAergic drive onto layer 2/3 pyramidal neurons in the 
visual cortex is decreased with loss of maternal E6AP, which arises from an 
accumulation of clathrin-coated vesicles at inhibitory axon terminals in 
interneurons. However, excitatory interneuron input is not affected, suggesting 
that the excitatory/inhibitory balance is neuron-specific (Wallace et al., 2012). 
Furthermore, selective loss of E6AP in GABAergic neurons causes AS-like 
neocortical EEG patterns, enhancing seizure susceptibility, and leads to 
presynaptic accumulation of clathrin-coated vesicles, whereas specific 
glutamatergic loss has no effect on EEG patterns (Judson et al., 2016). 
Decreased tonic inhibition has also been found in cerebellar granule cells of 
E6AP-deficient mice (Egawa et al., 2012). E6AP was found to control the 
degradation of the GABA transporter 1 (GAT1) in cerebellar granule cells, 
leading to an increase in GAT1 with loss of E6AP and resulting in decreased 
GABA concentrations in the extrasynaptic space. Additionally, treatment of a 
selective GABAA receptor agonist improved the firing properties of cerebellar 
cells in brain slices and reduced cerebellar ataxia in Ube3Am-/p+ mice, further 
supporting the role of neuron-specific effects of E6AP loss resulting in the 
manifestations of various behavioral phenotypes in AS (Egawa et al., 2012).  
Abnormalities in dopamine signaling have been found in Ube3Am-/p+ mice. 
Although the number of dopaminergic cells and dopamine synthesis are normal 
in these AS mice, increased dopamine release was observed in the mesolimbic 
pathway, while the nigrostriatal pathway exhibited decreased dopamine release 
  
37 
(Riday et al., 2012). Decreased GABA co-release was also found as a result of 
E6AP loss from tyrosine hydroxylase-expressing dopaminergic neurons in the 
ventral tegmental area, leading to enhanced reward-seeking behavior (Berrios et 
al., 2016). Interestingly, clinical administration of levodopa (L-DOPA) in a small 
number of AS patients dramatically improved resting tremor and rigidity 
symptoms (Harbord, 2001). These studies suggest that although defects in the 
dopaminergic pathway may not account for all neurodevelopmental affects of 
E6AP loss, it may be involved in causing some of the symptoms arising from 
dopaminergic signaling  
 
1.4 Neuronal morphological changes in ASDs 
Due to the genetic heterogeneity of ASDs, no single morphological phenotype 
has been observed that can be applicable to all ASDs. However, studies from 
postmortem human brains and an increasing number of ASD mouse models 
have been helpful in characterizing the changes occurring in neuronal 
development. One of the first reports of cortical neuron Golgi staining in tissue 
from human autism patients revealed that although spine morphology was 
normal, the density of spines along dendrites was decreased (Williams et al., 
1980). Decreased dendritic branching and numbers were also found in the 
hippocampus and prefrontal cortex of autism patients (Mukaetova-Ladinska et 
al., 2004; Raymond et al., 1996). However, brains of ASD patients have also 
  
38 
been shown to display greater dendritic spine densities in cortical pyramidal cells, 
along with decreased brain weight (Hutsler and Zhang, 2010).  
 Fragile-X (FXS) patients with FMRP mutations display abnormal dendritic 
branching and synaptic maturity (Rudelli et al., 1985). FXS patients exhibit an 
increased density of dendritic spines on distal segments of apical and basal 
dendrites in the cerebral cortex, which tend to have more of a longer, immature 
morphology than control brains (Hinton et al., 1991). Similar findings have been 
obtained from the FXS Fmr1 KO mouse model. FXS mice exhibit increased 
dendritic spine density, with an increase in longer, filopodia-like spines and 
decrease of shorter spines, signifying more immature spines and less mature 
spines (Comery et al., 1997; Galvez et al., 2003; Irwin et al., 2002; McKinney et 
al., 2005). Interestingly, some studies have reported higher spine densities 
earlier during development at 1 week of age, but normal spine density at 2 weeks 
of age, suggesting that spinogenesis may occur in excess in FXS, but pruning of 
the excess spines brings density back to normal (Cruz-Martin et al., 2010; 
Nimchinsky et al., 2001).  
 Rett syndrome (RTT) patients also display abnormalities in dendrite and 
spine morphology. Specifically, Golgi studies of the cerebral cortex of RTT 
patients have revealed reduced dendritic arborization in layer 3 and 5 pyramidal 
neurons, along with decreased dendritic spine density, accompanied by a 
decreased proportion of mushroom-type spines within the cortex and 
hippocampus (Armstrong et al., 1995; Belichenko et al., 1994; Chapleau et al., 
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2009). Interestingly, levels and phosphorylation of the microtubule stabilizing 
proteins MAPs are altered during dendritic formation in RTT patients (Kaufmann 
et al., 2000). Morphological changes involved in Rett syndrome have been 
recapitulated by knocking out MECP2, the gene mutated in RTT that encodes the 
methyl CpG binding protein 2. MeCP2 KO mice have abnormal dendritic spine 
morphology as well as decreased dendritic arbor complexity (Chapleau et al., 
2012; Fukuda et al., 2005). Interestingly, one of the genes regulated by MeCP2 
is BDNF, and its expression is lowered in RTT, implicating a direct mechanism 
for dendrite and spine dysgenesis during development (Chang et al., 2006; Li et 
al., 2012; Wang et al., 2006). Similarly to FXS mice, however, dendritic spines 
changes are observed before the age of P15 in mice, suggesting that a 
compensatory mechanism may take place following that developmental period 
(Chapleau et al., 2012).  
 Studies of other ASDs genes show morphological deficits in spines and 
dendrites as well. Shank overexpression in hippocampal neurons leads to the 
maturation and enlargement of dendritic spine heads, whereas inhibiting its 
targeting to synapses reduces spine density and size (Sala et al., 2003; Sala et 
al., 2001). Deletion of either TSC1 or TSC2, the genes involved in tuberous 
sclerosis, results in enlargement of somas and dendritic spines, as well as 
Purkinje cell loss, correlating with cerebellar dysfunction in mouse models (Reith 
et al., 2013; Tavazoie et al., 2005; Tsai et al., 2012). Additionally, the X-linked 
autism protein KIAA2022/KIDLIA leads to impairments in neurite outgrowth (Van 
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Maldergem et al., 2013). Specifically, KIDLIA knockdown in mice leads to altered 
neuron migration and reduced dendritic growth and branching by mediating N-
cadherin and δ-catenin signaling (Gilbert and Man, 2016). Cumulatively, there is 
strong evidence that the molecular changes that underlie the behavioral deficits 
in ASDs may be due by impairments in dendrite and spine development.  
 
1.5 Thesis rationale 
Loss of function of UBE3A/E6AP results in the manifestation of Angelman 
syndrome, whereas duplication and triplication of the gene causes autism, 
suggesting a dosage-dependent role for E6AP in neuronal development. Given 
that dendrite and dendritic spine development and morphology are essential to 
proper brain function, and given that changes in morphology have been found in 
ASD patients, we hypothesize that E6AP directly affects dendrite morphology 
and that this function is related to the underlying cause of E6AP-dependent ASD. 
Although correlation between E6AP dosage and morphology has been previously 
made, how the function of E6AP itself leads to changes in morphology is still 
unclear. Furthermore, the role of E6AP has been studied primarily for its 
implication in AS and less for its implication in ASD. We hypothesize that the 
function of E6AP as an E3 ligase leads to changes in dendritic development and 
aim to identify novel ubiquitination targets relevant to these changes. We will use 
cultured primary neurons and in vivo ASD mouse model to investigate the 
  
41 
cellular processes and molecular signaling cascades involved in E6AP-
dependent dendritic maturation and remodeling.  
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CHAPTER TWO: MATERIALS AND METHODS 
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2.1 Antibodies 
Primary antibodies to the following proteins were used: mouse anti-E6AP (1:100 
for ICC and IHC, 1:1000 for WB, Sigma-Aldrich Cat #8655), rabbit anti-cleaved 
caspase 3 (1:100 for ICC, 1:1000 for WB, Cell Signaling Cat #9661), rabbit anti-
caspase 3 (1:1000 for WB, Cell Signaling Cat #9662), rabbit anti-XIAP (1:100 for 
ICC and IHC, Bioss Antibodies Cat #bs-1281r), rabbit anti-XIAP (1:1000 for WB, 
Sigma-Aldrich cat #PRS3331), mouse anti-FLAG tag DYKDDDDK (1:1000 for 
WB, Cell Signaling Cat #8146), anti-GAPDH (1:5000 for WB, EMD Millipore Cat 
#MAB374), mouse anti-alpha tubulin (1:2000 for WB, Sigma-Aldrich Cat 
#T9026), rabbit anti-cleaved tubulin (TubΔCasp6) (1:500 for ICC, 1:5000 for WB, 
provided kindly by Andrea LeBlanc at McGill University), mouse anti-NeuN 
(1:100 for ICC, EMD Millipore), rabbit anti-GluA1 (1:250 for ICC, 1:1000 for WB, 
made in house), rabbit anti-SCR (1:250 for ICC, 1:1000 for WB, ProSci Inc.), 
rabbit anti-eIF4E (1:250 for ICC, 1:1000 for WB, Cell Signaling), and rabbit anti-
eIF4G (1:250 for ICC, 1:1000 for WB, Cell Signaling). The following secondary 
antibodies were used: IgG-HRP for WB (1:5000, BioRad mouse, Cat #170-6516, 
and rabbit Cat #170-6515), mouse Alexa Fluor 488 (1:500, Molecular Probes Cat 
#A21121), rabbit Alexa-Fluor 488 (1:500, Molecular Probes Cat #A11094), 
mouse Alexa Fluor 555 (1:500, Molecular Probes Cat #A21127), and rabbit Alexa 
Fluor 555 (1:500, Molecular Probes Cat #A21428).  
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2.2 Plasmids  
The following cDNA plasmids were obtained from Addgene: p4054-E6AP 
(#8658), E6AP C820A (#37602), pEBB-XIAP (#11558), and pCDNA3-Caspase 3 
C163A (#11814). mCherry-tubulin WT and mCherry-tubulin K40A were a kind gift 
from Dr. Saudou Frederic (Institut Curie), SCRAPPER-GFP was a kind gift from 
Dr. Mitsotoshi Setou (Mitsubishi Kagaku Institute of Life Sciences), HA-ubiquitin 
and Nedd4 were kindly provided by Dr. Peter Snyder (University of Iowa).  
 pHR-pTRE-iCre-mCherry and pHR-rtTA (Tet-ON) were generously 
provided by Wilson Wong. To make pHR-pTRE-E6AP-mCherry, full length 
human E6AP was PCR amplified to include the restriction sites MluI and XmaI 
using the following oligonucleotides: 5’ 
GCACGCGTGATGGAGAAGCTGCACCAG 3’, 5’ 
GTCCCGGGGCAGCATGCCAAATCCTTT 3’. The same restriction sites were 
cut in pHR-pTRE-iCre-mCherry to remove iCre. E6AP PCR products were gel-
purified (QIAGEN QIAquick Gel Extraction Kit) and subcloned into the vector. 
Similarly, pHR-pTRE-E6AP (without mCherry) was constructed using the 
restriction sites MluI and NotI and the following oligonucleotides: 5’ 
GCACGCGTGATGGAGAAGCTGCACCAG 3’, 5’ 
GTGCGGCCGCGTTACAGCATGCCAAATCCTTT 3’. To make AAV E6AP, 
E6AP was subcloned into AAV-ReaChR-citrine (Addgene #50954) using the 
BamHI and HindIII restriction sites.  
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2.3 Drugs  
Doxycycline (Sigma Aldrich Cat #D9891) was used at 1 µg/ml. MG132 
was obtained from Sigma-Aldrich (Cat #7449). The caspase-9 inhibitor III Ac-
LEHD-CMK, was obtained from EMD Millipore (Cat #218728). Tubulin live-cell 
fluorescent labeling was done with the SiR-Tubulin Spirochrome probe 
(Cytoskeleton, Inc. Cat # CY-SC002) according to manufacturer’s instructions.  
 
2.4 Neuronal and HEK cell culture and transfection 
Primary cultured cortical and hippocampal neurons were prepared from 
embryonic day 18 rat. Cerebral hemispheres from E18 rat brains were collected 
in Hanks balanced salt solution (HBSS), and the meninges were removed before 
the hippocampus and cortex were separated. The tissues were then transferred 
to a digestion solution made of 14 ml HBSS, 0.1 5ml 500mM EDTA pH 8.0, 0.5 
ml 4 mg/ml L-cysteine, and 0.5 ml 15 mg/ml papain, and incubated in a 37°C 
water bath for 20min. Tissues were then transferred to a trituration solution (21 
ml HBSS, 27 µl 1% DNAse, 3ml 10/10 solution (HBSS with 10 mg/ml BSA and 
10 ml/ml chicken egg white partially purified Ovomucoid)) and triturated until 
disuse was dissociated. Neurons were counted using a hemocytometer and 
seeded onto Poly-L-lysine (Sigma-Aldrich) coated coverslips in 60mm dishes, 
each containing five coverslips, 6-well plates, or glass-bottom 6-well plates (In 
Vitro Scientific). Neurons were maintained in Neurobasal medium 
(ThermoFisher), supplemented with 2% Neurocult TM SM1 Neuronal Supplement 
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(StemCell Technologies), 1% horse serum (Atlanta Biologicals), 1% 
penicillin/streptomycin (Corning), and L-Glutamine (Corning). Seven days after 
plating, 5’-Fluoro-2’-Deoxyuridine (FDU) (10 µM, Sigma-Aldrich) was added to 
the neuron media to suppress glial growth until experimental use.  
Human embryonic kidney (HEK) 293T cells (ATCC® CRL-3216) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Corning) supplemented 
with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), 1% 
penicillin/streptomycin, and L-glutamine. All cells were maintained in a humidified 
incubator at 37°C in an atmosphere containing 5% CO2.  
 
2.5 Plasmid transfection and viral infection  
2.5.1 Transfection  
Neuron transfections were performed at DIV10-11 with Lipofectamine 2000 
(Invitrogen) according to manufacturer’s instructions with a DNA to Lipofectamine 
ratio of 2:1. Briefly, DNA and Lipofectamine were separately diluted in DMEM, 
then mixed together and incubated for 20 min at room temperature. The mixture 
was then added to neuron coverslips or glass-bottom plates and incubated for 4 
hours at 37°C, after which the transfection medium was replaced with 
conditioned neuron medium. Neurons were fixed for immunocytochemistry 24-36 
hours after transfection. HEK cell transfections were performed similarly at 60-
70% cell confluency using the polyethylenimine (PEI) transfection reagent 
(Polysciences) with a 3:1 PEI to DNA ratio. The cells were incubated with the 
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transfection mixture for 8 hours, then rinsed twice with sterile PBS, and replaced 
with fresh HEK medium. HEK cells were lysed and collected 48 hours after 
transfection.  
 
2.5.2 Virus production and infection  
Recombinant adeno-associated virus (AAV) was produced by 
transfecting HEK293T cells with the E6AP AAV or GFP AAV plasmid, along with 
viral packaging and envelope proteins XX6.80 and p50-Cap9 (AAV9) or XR2 
(AAV2) using PEI. Three days following transfection, cells were lysed by 
freeze/thaw cycles and sonicated. The lysate was centrifuged at 3000 x g for 30 
minutes at 4°C and the supernatant was filtered through a 0.45 µm filter and 
precipitated with PEG-IT (Systems Biosciences). The mixture was centrifuged at 
1500 x g for 30 minutes and the resulting viral pellet was resuspended in PBS 
and aliquots were kept at -80°C. Primary neurons were infected with virus at 
DIV2 and collected at DIV 12.  
 
2.6 Transgenic animals  
2.6.1 Animal maintenance   
FVB/NJ-Tg(Ube3A)1Mpan/J mice (stock 019730) and FVB/NJ wild-type mice 
(stock 001800) were purchased from the Jackson Laboratory. All animals were 
maintained in accordance with guidelines of the Boston University Institutional 
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Animal Care and use Committee. To obtain Ube3A 2X Tg animals, heterozygous 
males were mated with heterozygous females and homozygous animals were 
used for experiments.  
 
2.6.2 Genotyping  
Tail snips were collected from mice and DNA was extracted by incubation with a 
base solution (25 mM NaOH, 0.2 M EDTA, pH 12) at 95°C for 30 minutes, 
followed by addition of a neutralization solution (40 mM Tris-HCl, pH 5). PCR 
was performed using 2 µl of the extracted DNA with a 2720 Thermo Cycler 
(Applied Biosystems) with the following conditions: initial hold at 94°C for 2 min, 
followed by 25 cycles of a 20 sec denaturing step at 94°C, a 15 sec annealing 
step at 65°C (with 0.5°C stepdown/cycle), and a 10 sec extension step at 68°C; 
followed by 25 cycles of another 15 sec denaturing step at 94°C, a 15 sec 
annealing step at 60°C, and a 10 sec extension step at 72°C, followed by a final 
extension step of 2 min at 72°C. PCR fragments were run on a 1.5% agarose gel 
with ethidium bromide to label DNA and visualized under UV light.  
 Two separate PCR reactions were run side by side. One for the Ube3A 
transgene with the following primers: forward primer                                           
5’-GAAAACGGATACCAAGGCG-3’ and reverse primer  
5’-TAGTCAATTCACCATCTTGTT- 3’, and another for an internal positive control 
with the forward primer 5’ - CTAGGCCACAGAATTGAAAGATCT- 3’ and the 
reverse primer 5’- GTAGGTGGAAATTCTAGCATCATCC-3’. A 324 bp band for 
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the internal control without the transgene band signified a WT animal, whereas a 
324 bp band with a faint transgene band at 691 identified a heterozygous animal, 
and a 324 bp band with a strong transgene band identified a homozygous 
animal.  
2.7 Immunostaining and microscopy  
2.7.1 Immunocytochemistry 
Hippocampal neurons were washed twice in ice-cold ACSF and fixed for 10 min 
in a 4% paraformaldehyde/4% sucrose solution at room temperature. Cell 
membranes were permeabilized for 10 min with 0.3% Triton-X-100 (Sigma-
Aldrich) in PBS, rinsed three times with PBS, then blocked with 5% goat serum in 
PBS for 1 hr. Following blocking, cells were incubated with primary antibodies 
made in 5% goat serum for 1 hr at room temperature, washed with PBS and 
incubated with Alexa Fluor-conjugated secondary antibodies for 1 hr. Cells were 
then mounted on microscopy glass slides with Prolong Gold anti-fade mounting 
reagent (Thermo Fisher Cat # P36930) for subsequent visualization.  
 
2.7.2 Immunohistochemistry  
For brain slices, animals were anesthetized in a CO2 chamber and transcardially 
perfused with ice-cold PBS. The brains were removed and placed in 4% 
paraformaldehyde in PBS solution at 4°C for 4-6 hrs, followed by incubation in a 
30% sucrose PBS solution at 4°C for 24 hrs. The brains were then placed in 
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trays, submerged in OCT embedded medium (Tissue-Tek Cat. #25608-930), and 
flash frozen by placing the trays in a dry ice bath with methanol. Frozen brains 
were cut in 20 µm sections on a Leica CM 1850 cryostat (Leica Biosystems) at -
20°C. Slices were then rehydrated in PBS for 40 min, followed by blocking and 
permeabilization in a 5% goat serum solution with 0.3% Triton-X 100/PBS for 1.5 
hrs. Slices were than incubated with primary antibodies made in 5% goat serum 
overnight at 4°C, washed three times with PBS, and incubated with secondary 
antibodies in 5% goat serum for 1 hr. Nuclei were stained with Hoechst, followed 
by three washes with PBS, and coverslipping with coverglass (Fisherbrand #12-
544-D) with Prolong Gold. For GFP AAV2-infected brains, 100 µm slices were 
made, rehydrated, and stained with Hoechst before coverslipping. These 
procedures were reviewed and approved by the Boston University Institutional 
Animal Care and Use Committee.  
 
2.7.3 Golgi staining  
Whole brains collected from transgenic animals at P15 were subjected to Golgi-
Cox neuron staining according to the manufacturer’s instructions (FD 
Neurotechnologies Rapid Golgistain Kit, Cat #PK401). Brains were sliced in 200 
µm -thick slices using a cryostat. Stained slices were mounted on gelatin-coated 
microscopy slides (FD Neurotechnologies Cat #PO101) with Permount mounting 
medium (Fisher Scientific). Images obtained from Golgi-stained slices were 
traced using ImageJ for spines and NeuronJ for dendrites.  
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2.7.4 Microscopy 
Hippocampal neurons mounted on glass slides were imaged with a Carl Zeiss 
inverted fluorescent microscope with a 40X or 63X oil-immersion objective and 
collected with AxioVision 4.5 software. Golgi stained brain slices were imaged 
with a 20X air objective. Images were quantified using NIH ImageJ software.  
Fixed brain sections from transgenic animals were imaged using a Zeiss 
LSM 700 laser scanning confocal microscope with a 25X oil-immersion objective. 
Images were collected as 4x4 tiles and stitched together using the Zen imaging 
software.  
Live images of hippocampal neurons were obtained with a Zeiss LSM 700 
Laser Scanning Confocal Microscope with a 63X oil-immersion objective in a 
temperature-controlled live imaging chamber. Images of the same cells were 
obtained at several time points from induction of expression with the Zen imaging 
software.  
 
2.7.5 Sholl Analysis 
Dendritic arborization was quantified using Image J. Original images of neurons 
were used to trace dendrites with the NeuronJ plugin. Using the Sholl Analysis 
plugin, the center of the soma was used as a reference point and ten concentric 
circles were made on the tracings: the starting radius was set to 35 pixels and 
the ending radius was set to 800 pixels (the outermost circle within the image). 
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From these parameters, the number of intersections at each concentric circle 
was quantified and plotted.  
 
2.8 Immunoblotting  
2.8.1 Sample collection  
Brains were collected from transgenic animals at various developmental stages 
(postnatal day 0 to postnatal day 40) and the hippocampus was dissected out. 
Brain tissues were either processed immediately or frozen at -80°C for later 
processing. Tissues were lysed in RIPA buffer with 0.1% sodium dodecyl sulfate 
by trituration, followed by brief sonication, and incubation for 1 hr on a rotator at 
4°C. Samples were then centrifuged at 13,000 rpm for 30 min at 4°C and the 
supernatant was collected. Protein levels were quantified by BCA assay (Pierce) 
and normalized to the same total protein concentration. 
 
2.8.2 Immunoprecipitation 
For ubiquitination immunoprecipitation assays, cells were rinsed with cold 
phosphate-buffered saline and resuspended in 200 µl modified 
radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris–HCl pH 7.4, 150 
mM NaCl, 1% NP-40 (Affymetrix/USB, Santa Clara, CA, USA), 1% sodium 
deoxycholate and 1% sodium dodecyl sulfate) with mini complete protease 
inhibitor (Roche, Indianapolis, IN, USA) and 20 µM N-Ethylmaleimide (NEM, 
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Sigma). Lysates were further solubilized by sonication and volumes were 
adjusted to 500 µl with more RIPA buffer. Protein A sepharose beads (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) were added to the lysates along with 
antibodies against either FLAG or XIAP and samples were incubated overnight 
for 12-16 hours on rotation at 4°C. Immunocomplexes were washed three times 
with cold RIPA buffer, resuspended in 2X Laemmli buffer, and denatured at 95°C 
for 10 min before being subjected to western blotting.  
 
2.8.3 Western Blotting  
Cell lysates or immunoprecipitates were separated by SDS-PAGE, transferred to 
PVDF membranes, and probed with the appropriate antibodies. Immunointensity 
of western blots was measured using Image J; values were normalized to 
corresponding tubulin or GAPDH inputs, and then normalized to controls where 
appropriate prior to statistical analysis. 
 
2.9 Statistical analyses  
Data from multiple trials were averaged to obtain the mean for each experiment. 
Multiple means of the same condition were averaged to obtain the standard error 
of the mean, represented by the error bars in all graphs. Statistical analysis was 
performed using two-population Student’s t-test. An unpaired Student’s t-test or 
one-way ANOVA with post-hoc Tukey’s test was used as appropriate.  
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3.1 Abstract  
UBE3A gene copy number variation and the resulting overexpression of the 
protein E6AP is directly linked to Autism spectrum disorders (ASDs), however, 
the underlying cellular and molecular mechanisms related to ASD remain less 
clear. Here we report the role of ASD-related increased dosage of E6AP in 
dendritic arborization during brain development. We show that increased E6AP 
expression in primary rat neurons leads to a reduction in dendritic branch number 
and length. The E6AP-dependent remodeling of dendritic arborization results 
from pruning of dendrites with thinning and fragmentation at the distal tip, leading 
to shortening or removal of dendrites. This pruning effect is mediated by the 
ubiquitination and degradation of X-linked inhibitor of apoptosis (XIAP) by E6AP, 
which leads to activation of executioner protease caspase-3 and cleavage of 
microtubules. Consistently, Ube3A 2X ASD mice show decreased XIAP levels, 
increased caspase-3 activation, and elevated levels in tubulin cleavage. 
Interestingly, dendritic branching and spine density are reduced in cortical 
neurons of Ube3A ASD mice. Our findings reveal an important role for 
UBE3A/E6AP in ASD-related developmental alteration in dendritic arborization 
and synapse formation, which provide new insights into the pathogenesis of 
E6AP-dependent ASD.  
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3.2 Results  
3.2.1 E6AP overexpression leads to a reduction in dendritic arborization  
To investigate whether E6AP has any role in neuron morphogenesis, we 
overexpressed E6AP together with surface GFP in cultured rat hippocampal 
neurons at DIV11 and observed their morphology at DIV12. Twenty-four hrs after 
transfection, increased levels of E6AP expression were detected in both the 
soma and the dendrites of neurons, as shown by staining of E6AP (Figure 3.1A, 
3.1B). At this stage, control neuron morphology shows multiple primary dendritic 
branches deriving from the soma, with elaboration of second and third order 
branches.  Primary branches are distributed roughly evenly around the soma, 
often with one major, dominant dendrite (Figure 3.2A). Surprisingly, compared to 
the GFP-only control, E6AP-transfected neurons revealed a marked reduction in 
dendritic morphology. Typically, a large portion of the dendrites disappeared, 
leaving only one or two major primary branches with multiple short minor neurites 
at the soma region (Figure 3.2A). Sholl analysis showed that the dendritic branch 
numbers were significantly decreased along the distance from the soma (Figure 
3.2B). The total number of dendrites and total dendritic length were also 
significantly reduced in E6AP-transfected neurons (branch number, control: 41.6 
± 3.3; E6AP: 17.5 ± 1.41, p < 0.001; total length, control: 2299.9 ± 176.3 µm; 
E6AP: 877.4 ± 78.1 µm; p < 0.001; n = 40 cells per condition) (Figure 3.2C). 
Importantly, this effect was dependent on the dosage of E6AP expression, as 
knockdown of E6AP by siRNA resulted in an increase in dendritic branching  
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Figure 3.1 
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Figure 3.1 Cellular distribution of E6AP  
(A) Staining of endogenous E6AP (red) in control primary neurons transfected 
with surfGFP (green) only. E6AP is present in the soma and dendrites. (B) 
Staining of total E6AP (red) in neurons transfected with surfGFP (green) and 
E6AP. Increased levels of E6AP were detected in both the soma and dendritic 
arborization. Scale bar = 50 µm. 
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Figure 3.2 
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Figure 3.2 E6AP overexpression reduces the complexity of dendritic 
arborization. 
(A) Hippocampal neurons were transfected with surfGFP together with vector 
cDNA (Control) or E6AP cDNA at DIV11 and imaged for morphology 24 hrs after 
transfection. Scale bar = 50 µm. (B) Sholl analysis of dendritic branch numbers.  
Overexpression of E6AP resulted in a decrease in dendritic complexity; n = 40 
neurons for each condition. (C) Total dendritic branch number and total dendritic 
length were reduced in E6AP-transfected neurons; n = 40. (D and E) Dendrites 
were characterized as either primary, secondary, tertiary, or quaternary based on 
their arborization pattern. Representative images of neurons were traced with 
primary dendrites in blue, secondary in red, tertiary in cyan, and quaternary in 
magenta. E6AP overexpression led to a decrease in secondary and tertiary 
dendritic branch length; n = 10. Error bars represent SEM, t-test, *P < 0.05, **P < 
0.01. 
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Figure 3.3  
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Figure 3.3 Downregulation of E6AP levels increases dendritic arborization 
complexity  
(A) Hippocampal neurons were transfected with surfGFP together with vector 
Scrambled siRNA or siRNA targeted to E6AP and imaged for morphology 24 hrs 
after transfection. (B) Sholl analysis of dendritic branch numbers.  
Overexpression of E6AP resulted in a decrease in dendritic complexity; n = 40 
neurons for each condition. Error bars represent SEM, t-test, *P < 0.05. 
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(Figure 3.3A, 3.3B). To further characterize the changes in dendritic morphology, 
we analyzed the branching pattern based on branching orders (Figure 3.2D). We 
found that although the length of primary branches was similar between both the 
control and E6AP conditions (control: 294.4 ± 50.4 µm, n = 10; E6AP: 231.1 ± 
37.7 µm, n = 10, p > 0.05), the secondary and tertiary branches were significantly 
reduced in length by E6AP overexpression (secondary branch, control: 378.6 ± 
37.8 µm, n = 10; E6AP: 207.3 ± 29.9 µm, n = 10, p < 0.05; tertiary branch, 
control: 442.4 ± 101.3 µm, n = 10; E6AP: 60.58 ± 12.5 µm, n = 10, p < 0.01) 
(Figure 3.2E). These data showed that overexpressing E6AP leads to a reduction 
in dendritic arborization complexity in primary hippocampal neurons.  
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3.2.2 Overexpression of E6AP in primary hippocampal neurons decreases 
mature spines  
E6AP overexpression caused a drastic reduction in dendrite branching and 
length. We next wanted to know whether E6AP also plays a role in the regulation 
of dendritic spines. One possibility is that, as a result of a reduction in dendritic 
arborization, the remaining dendrites may have an increased density of spines to 
compensate for the loss of dendrites; or, E6AP may have a general effect on 
growth that will cause suppression on the dendrites as well as the spines. To 
examine these possibilities, we transfected neurons at DIV11 with E6AP and 
surface GFP (surfGFP), which contains a membrane attachment motif and is 
thus able to clearly delineate the minor membranous structure such as the spines  
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Figure 3.4  
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Figure 3.4 Overexpression of E6AP in primary hippocampal neurons 
decreases mature spines 
(A) Images of dendritic spines from neurons transfected at DIV11 with surfGFP 
or together with E6AP for 24 hrs. Scale bar = 10 µm. (B) Mean spine density was 
decreased in E6AP neurons; n = 10 cells. (C) Spines were categorized as either 
mushroom, stubby, thin, or filopodia. Increased E6AP expression led to a 
decrease in mushroom-type spines and an increase in filopodia; n = 10 cells. 
Error bars represent SEM, t-test, *P < 0.05, **P < 0.01, ***P < 0.001.    
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(Kameda et al., 2008) (Figure 3.4A). Twenty-four hrs after transfection, neurons 
were fixed and spines were counted on 50 µm segments along primary 
dendrites. Mean spine density was decreased in E6AP overexpressing neurons 
(control: 0.84 ± 0.09 spines/µm, n = 10 cells; E6AP: 0.27± 0.02 spines/µm, n = 10 
cells; p < 0.05) (Figure 3.4B). Upon further characterization of the subtypes of 
spines, we found that E6AP neurons had decreased mushroom-type spines 
(control: 21.6 ± 3.3%, n = 10; E6AP: 7.4 ± 1.9%, n = 10, p < 0.01) (Figure 3.4C). 
Conversely, the percentage of filopodia was increased in E6AP neurons (control: 
6.8 ± 3%, n = 10; E6AP: 20.2 ± 6.4%, n = 10, p < 0.05) (Figure 3.4C). The 
percentage of stubby spines and thin spines was not significantly different 
between control and E6AP (Figure 3.4C). The decrease in mushroom spines and 
increase in filopodia in E6AP-transfected neurons suggests a role for E6AP in 
suppression of spine maturation during neuron development.  
 
3.2.3 E6AP overexpression causes active dendrite elimination 
We wanted to determine whether the change in dendritic morphology was a 
result of an inhibition in growth or caused by active removal of existing dendritic 
branches. To this end, hippocampal neurons were transfected at DIV10 with 
surfGFP, and fixed after 24 hrs at DIV11 for morphological analysis (Figure 3.5A 
and 3.5B). At DIV11, another set of neurons was transfected with either surfGFP 
only or together with E6AP, and fixed 24 hrs later at DIV12. This would allow 
visualization of neuron morphology at the time of transfection (DIV11) to facilitate  
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Figure 3.5  
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Figure 3.5 E6AP overexpression triggers active dendrite elimination.  
(A) A diagram of the experimental design. Neurons were transfected at DIV10 for 
24 hrs and another set of neurons was transfected at DIV11 for 24 hrs. (B) GFP 
images of neurons transfected from DIV10 to DIV11 or from DIV11-DIV12. Scale 
bar = 50 µm. (C) Sholl analysis showed reduced dendritic arborization in E6AP 
neurons at DIV12 compared to either DIV11 or DIV12 control cells; n=10 cells 
per condition. Error bars represent SEM, t-test, **P < 0.01.  
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comparison to neurons 24 hrs later (DIV12). At DIV11, the hippocampal cultured 
neurons already have elaborate dendritic arborization (Figure 3.5B). If E6AP 
simply suppresses dendrite growth, arborization of E6AP-exressing neurons at 
DIV12 is expected to be similar to the DIV11 control neurons. However, 
compared to the surfGFP control neurons fixed at DIV11, overexpressing E6AP 
from DIV11 to DIV12 still led to a reduction in dendritic arborization (significant 
difference in number of intersections at 40-132 µm, n = 10, p < 0.01) (Figure 
3.5C). This suggests that the E6AP-induced down-regulation in dendrite 
branching was not likely due to an inhibition of dendrite growth, but rather an 
active removal of existing dendritic branches.  
To further examine the cellular process leading to reduced dendritic 
complexity, we carried out live imaging with inducible E6AP expression. We first 
tested our tetracycline-inducible E6AP for its ability to change dendrite 
morphology. Indeed, expression of pTRE-E6AP-mCh after doxycycline (1 µg/ml) 
treatment caused significant dendrite reduction within 24 hrs, while untreated 
pTRE-E6AP-mCh cells did not (Figure 3.6A, 3.6C). In contrast, expression of the 
control pTRE-mCh did not lead to changes in morphology with or without 
doxycycline treatment (Figure 3.6A, 3.6B). To study the molecular process of 
pruning, hippocampal cultures on a glass-bottom plate were transfected with 
surfGFP together with either pTRE-mCh (control) or pTRE-E6AP-mCh. One day 
after transfection, when neuron structure became clearly visible with surfGFP, 
doxycycline was added to the medium to induce E6AP expression and neurons 
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were imaged every 6 hrs for the next 24 hrs. We found that in the control 
neurons, while there was some minor dendrite growth and pruning, the overall 
structure remained stable (Figure 3.7A, top row). In contrast, the dendritic arbors 
of the E6AP-expressing neurons changed drastically over the same period of 
time. A large portion of preexisting dendrites was removed, while a smaller 
number of neurites either grew or remained stable (Figure 3.7A, middle row). 
Compared to control, E6AP neurons had more pruning events (control: 35.5 ± 
7.8%, n = 9; E6AP: 49.09 ± 5.2%, n = 7, p < 0.05) (Figure 3.7B) and a greater 
percentage of overall pruning (control: 17.57 ± 4.6%, n = 9; E6AP: 39.4 ± 6.8, n = 
7, p < 0.05) (Figure 3.7C), indicating an elevated activity in dendritic pruning. The 
total length of growth was not significantly different in E6AP neurons, supporting 
that the reduction in dendritic arbor complexity is not a result of inhibition of 
growth (Figure 3.7D). The total length of pruned branches was significantly 
increased in E6AP cells (control: 73.8 ± 25.4 µm, n = 9; E6AP: 310.9 ± 62.8 µm, 
n = 7, p < 0.05), suggesting that the dendrites of E6AP neurons are reduced by 
active pruning (Figure 3.7E). Interestingly, we observed that the dendrites in the 
process of pruning showed two typical structural changes: distal thinning and 
fragmentation (Figure 3.7A, bottom row). Some dendrites were found to be 
thinning at the distal section close to the tip and shrinking before completely 
elimination, whereas others were found to become disintegrated into fragments 
at the tip of the neurite and gradually breaking down before disappearance.  
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Figure 3.6  
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Figure 3.6 Tet-induced expression of E6AP-mCherry causes dendritic 
pruning 
(A) Primary neurons were transfected with surfGFP (green) and Tet-ON, together 
with control pTRE-mCherry or pTRE-E6AP-mCherry. Twenty-four hrs after 
transfection, expression of the plasmids was induced by application of 
doxycycline (Dox, 1µg/ml) for 24 hrs. Scale bar = 50 µm. (B) Sholl analysis of 
control neurons with or without Dox treatment; n = 20 cells. (C) Sholl analysis of 
pTRE-E6AP-mCh neurons with or without Dox. Expression of E6AP led to 
decreased dendritic arborization under the Dox condition; n = 20 cells. Error bars 
represent SEM, t-test, *P < 0.05.  
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Figure 3.7  
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Figure 3.7 E6AP overexpression triggers active dendrite elimination.  
(A) DIV11 hippocampal neurons were transfected with pTRE-mCherry (Control) 
or pTRE-E6AP-mCherry (E6AP) and their expression was induced by the 
addition of doxycycline (Dox, 1µg/ml) 24 hrs after transfection. Live imaging was 
performed immediately after Dox treatment (time 0), and every 6 hrs for 24 hrs. 
Colored tracings represent dendrites that increased in length (green), decreased 
in length (red), or remained the same (yellow). A portion of dendrites was 
enlarged (bottom row) to show dendrite retraction and fragmentation in E6AP 
neurons. Scale bar = 50 µm. Scale bar for bottom insert = 10 µm.  (B) Analysis of 
live imaging dendritic events. A significant increase in pruning events was 
detected in E6AP-expressing neurons compared to the control neurons. (C) 
Percentage of total length of pruned dendrites at 24 hrs. (D) Total length of 
dendritic growth after 24 hrs. (E) Total length of dendritic pruning after 24 hrs; n = 
9 cells for control and n = 7 cells for E6AP for live imaging experiments. Error 
bars represent SEM, t-test, *P < 0.05, **P < 0.01.   
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3.2.4 Caspase-3 activity is required for E6AP-induced dendritic pruning 
Caspases are a family of cysteine proteases that play a key role in the signaling 
cascade involved in apoptosis, differentiation, and neuromorphogenesis (Unsain 
and Barker, 2015). An activated caspase cleaves and activates downstream 
caspases, leading to digestion of target functional proteins, and resulting in wide 
range cellular destruction as well as functional modification. In addition to global 
activation leading to cell death, activation of the caspase cascade has been 
found to occur locally at restricted regions in neurons (Li et al., 2010).  In cultured 
hippocampal neurons, caspase activity has been shown to be required for spine 
elimination (Erturk et al., 2014; Jiao and Li, 2011). Consistently, caspases also 
play an important role in synaptic plasticity (Li et al., 2010). More importantly, in 
line with the requirement for protein cleavage in structural remodeling, localized 
caspase activity has been implicated in the pruning of dendrites and axons in 
Drosophila during metamorphosis (Kuo et al., 2006; Kuranaga et al., 2006; 
Williams et al., 2006b). We wondered whether this pathway is involved in E6AP-
dependent dendritic reorganization. To this end, we first measured caspase-3 
activity in neurons overexpressing E6AP, as caspase-3 is a crucial downstream 
executioner caspase in the cascade. Hippocampal neurons were transfected with 
surfGFP alone or together with E6AP at DIV11 and fixed 24 hrs later. When 
neurons were immunostained with an antibody specifically against cleaved 
caspase-3 (activated form), we found that the E6AP-transfected neurons had a 
4.8-fold increase in cleaved caspase-3 levels compared the control (n = 10, p < 
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0.001) (Figure 3.8A, 3.8B). To further confirm the effect of E6AP on caspase-3 
activation, we infected neurons with AAV9 GFP or AAV9 E6AP virus for 10 days. 
Consistent with the immunostaining results, western blotting showed that cleaved 
caspase-3 levels were significantly increased in E6AP-infected neurons (2.04 ± 
0.07 fold normalized to control, n = 3, p < 0.01) (Figure 3.8C, 3.8D). We then 
wanted to investigate whether the caspase pathway is involved in E6AP-
dependent dendritic remodeling.  In hippocampal neurons transfected with E6AP, 
we suppressed caspase-3 activation by the application of Ac-LEHD-CMK (150 
nM), an irreversible inhibitor of caspase-9, which is an upstream activator of 
caspase-3 (Mocanu et al., 2000).  Indeed, treatment with the caspase-9 inhibitor 
completely blocked the E6AP-depdendent dendritic pruning (Figure 3.8E), 
indicating a requirement of caspase-3 activity in E6AP-induced dendritic 
remodeling. To further confirm the role of caspase-3, we performed dominant 
negative experiments. DIV11 neurons were transfected with E6AP along with a 
caspase-3 catalytic mutant plasmid, Casp3 C163A. Consistent with the 
pharmacological treatment, overexpression of this mutant caspase-3 abolished 
the E6AP-induced morphological changes (Figure 3.8F, 3.8G), demonstrating a 
clear rescue of the pruning phenotype by inhibition of caspase-3 cleavage and 
activity. These data strongly suggest that the caspase cascade, primarily 
caspase-3, plays a crucial role in E6AP-dependent dendritic remodeling in 
hippocampal neurons.  
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Figure 3.8  
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Figure 3.8 E6AP causes activation of caspase-3, which is required for 
dendritic pruning  
(A) Neurons were transfected with surfGFP (green) (Control) or together with 
E6AP, and the cleaved (activated) caspase-3 (red) was immunostained 24 hrs 
later. Scale bar = 50 µm. (B) Quantification of the cleaved caspase-3 
immnunofluorescence signals; n = 10. E6AP expression resulted in higher levels 
of cleaved caspase-3. (C and D) DIV2 hippocampal neurons were infected with 
AAV9 GFP virus or AAV9 E6AP virus for 10 d and cleaved caspase-3 levels 
were measured by western blot. Neurons infected with E6AP virus showed 
higher levels of cleaved caspase-3; n = 3 independent experiments. (E) Dendritic 
arborization reduction in E6AP neurons was blocked by inhibiting caspase-3 
cleavage with the caspase-9 inhibitor Ac-LEHD-CMK (150 nM) at the time of 
transfection, as shown by Sholl analysis; n = 10. (F and G) Neurons were 
transfected with surfGFP (control), or together with E6AP, or E6AP + Casp3 
C163A (E6AP + C3 mutant), a catalytic caspase-3 mutant. Scale bar = 50 µm. 
Sholl analysis revealed a rescue of the E6AP-induced dendritic pruning by Casp3 
C163A; n = 10. Error bars represent SEM, t-test, *P < 0.05, **P < 0.01, ***P < 
0.001.  
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3.2.5 E6AP as an E3 ligase targets XIAP for ubiquitination 
As E6AP is an E3 ligase, the ubiquitination and subsequent degradation of a 
tentative target protein(s) by E6AP must be involved. Indeed, when we 
expressed the E6AP E3 ligase mutant E6AP C820A, the dendritic pruning effect 
was reduced (Figure 3.9A, 3.9B), confirming the role of E6AP E3 ligase activity in 
pruning. Because E6AP expression led to an increase in caspase-3 activity, we 
hypothesized that it may target an intermediate molecule that inhibits caspases, 
so that ubiquitination and degradation of such an inhibitory molecule would lead 
to caspase-3 activation. In line with this thought, we found that the most likely 
candidate protein is the family of IAPs, the inhibitors of apoptosis. IAPs are the 
first identified family of endogenous cellular inhibitors of caspases in mammals; 
and members of that family, namely XIAP, c-IAP1, and c-IAP2, have been shown 
to potently bind to and inhibit caspases 3, 7, and 9 (Deveraux et al., 1997; Roy et 
al., 1997). Of these IAPs, XIAP is ubiquitously expressed in all adult and fetal 
tissues (Rajcan-Separovic et al., 1996), whereas c-IAP1 and c-IAP2 are mainly 
expressed in the kidney, small intestine, liver, and lung, with only minimal 
expression in the central nervous system (Young et al., 1999). XIAP, therefore, 
was considered the top candidate in mediating the E6AP effects. To directly 
investigate XIAP as a potential ubiquitination target, we performed ubiquitination 
assays as reported in our earlier studies (Huo et al., 2015; Lin et al., 2011). 
HEK293T cells were transfected with HA-ubiquitin, FLAG-XIAP, together with 
E6AP WT or E6AP C820A. Two days after transfection, FLAG-XIAP was isolated  
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Figure 3.9  
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Figure 3.9 The E3 ligase activity of E6AP is required for dendritic pruning. 
(A) Primary neurons were transfected with surfGFP, or together with E6AP, or 
the E3 ligase mutant E6AP C820A, and imaged 24 hrs later. Scale bar = 50 µm. 
(C) Cell morphology was analyzed by Sholl analysis, showing a significant 
decrease in dendritic arborization in neurons expressing regular E6AP, but not in 
cells expressing mutant E6AP C820A; n = 40 cells. Error bars represent SEM, t-
test, *P < 0.05,  ***P < 0.001. 
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Figure 3.10  
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Figure 3.10 E6AP targets XIAP for ubiquitination and degradation 
(A) XIAP ubiquitination assay. HEK293 cells were transfected with FLAG-XIAP, 
HA-Ubiquitin, and either a vector control, E6AP, or the E3 ligase dead mutant 
E6AP C820A for 2 d. XIAP was immunoprecipitated and probed for ubiquitin 
(ubi). Cell lysates (input) were also probed to detect total protein levels. (B) 
Quantification of western blot intensities. E6AP, but not E6AP C820A, caused an 
increase in XIAP ubiquitination and a decrease in XIAP protein levels; n = 3 
independent experiments. (C and D) XIAP ubiquitination assays using lysates of 
neurons infected with AAV9 GFP or AAV9 E6AP virus for 10 days. An increased 
amount of ubiquitination signals on XIAP was detected in E6AP-infected 
neurons; n = 3 independent experiments. Error bars represent SEM, t-test, *P < 
0.05, **P < 0.01.   
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by immunoprecipitation and probed for HA (ubiquitin). We found that compared 
to control, E6AP overexpression resulted in strong ubiquitination of XIAP (7 ± 
0.7-fold increase, n = 3, p < 0.01) (Figure 3.10A, 3.10B). In contrast, reduced 
ubiquitination was detected in cells expressing E6AP C820A, indicating E6AP as 
the E3 ligase for XIAP ubiquitination (2.5 ± 0.3-fold increase, n = 3, p > 0.05) 
(Figure 3.10A, 3.10B). To further confirm the XIAP ubiquitination by E6AP, we 
also performed a ubiquitination assay in neurons infected with either GFP or 
E6AP AAV9 virus for 10 days. Indeed, compared to GFP, E6AP virus caused a 
significant increase in XIAP ubiquitination (2.85 ± 0.12 fold increase, n = 3, p < 
0.05) (Figure 3.10C, 3.10D), further supporting XIAP as a ubiquitination target for 
E6AP.  
 
3.2.6 E6AP down regulates XIAP levels by ubiquitination-dependent 
degradation 
Following ubiquitination, the modified protein is usually sorted to the proteasome 
for degradation. To examine whether the E6AP-dependent XIAP ubiquitination 
leads to its degradation, we immunostained XIAP in neurons transfected with 
either a control vector or E6AP. As expected, the endogenous XIAP intensity was 
markedly reduced in neurons overexpressing E6AP (40 ± 9% n = 10, p < 0.05) 
(Figure 3.11A, 3.11B). Whole-cell lysates of E6AP-overexpressing HEK cells also 
had lower levels of XIAP, whereas XIAP levels in E6AP C820A cells were 
comparable to control (E6AP: 0.55 ± 0.06, n = 3, p < 0.01; E6AP C820A: 1.11 ± 
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0.1, n = 3, p > 0.05) (Figure 3.10A, 3109B). We further compared XIAP levels 
based on localization by measuring levels of XIAP immunostaining in major 
dendrites, minor dendrites, and the cell soma. We found that XIAP was 
specifically decreased in minor dendrites, perhaps indicating that the decrease of 
XIAP is involved in dendritic selectivity during E6AP-dependent remodeling 
(Figure 3.11C). To examine XIAP stability in neurons, we applied E6AP virus in 
hippocampal neurons for 10 days and probed XIAP by western blotting. Indeed, 
the total protein level of XIAP was markedly reduced in E6AP virus infected 
neurons (0.66 ± 0.07 n = 3, p < 0.01) (Figure 3.11D, 3.10E), confirming that 
E6AP indeed causes a reduction in XIAP protein levels.  
The E6AP-induced reduction in XIAP could result from facilitated 
degradation or inhibited protein synthesis.  To clarify this, we performed 
degradation assays in HEK293 cells. Two days after transfection with XIAP alone 
or together with E6AP, HEK cells were incubated with the protein translation 
inhibitor Cycloheximide (CHX) for varied periods of time. Western blots showed 
that XIAP had an increased rate of degradation in cells with E6AP 
overexpression compared to the control (at 6 hr for example, control: 0.49 ± 0.07; 
E6AP: 0.16 ± 0.06, n = 4, p < 0.05) (Figure 3.11F, 3.11G). This result confirmed 
that E6AP overexpression led to an elevated turnover rate for XIAP.  
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Figure 3.11 E6AP down regulates XIAP levels by ubiquitination-dependent 
degradation 
(A) Immunostaining of endogenous XIAP (red) in neurons transfected with 
surfGFP (green), or together with E6AP. Nuclei were indicated by DAPI staining  
(blue). Scale bar = 50 µm. (B) Quantification of the total XIAP signal intensity 
relative to the control; n = 10 cells per condition. (C) Quantification of XIAP signal 
by specific cell localization. (D and E) Neurons were infected with AAV9 GFP 
virus or AAV9 E6AP virus for 10 days, and XIAP levels were measured by 
western blot. Quantification showed a reduced level of XIAP in E6AP-infected 
neurons, n = 3 independent experiments. (F) Degradation assay of XIAP with or 
without E6AP. Transfected HEK cells were treated without Cycloheximide (CHX) 
for various time points and cell lysates were collected to examine XIAP levels by 
western blot. (G) Quantification of the degradation rate of XIAP over time; n = 4 
independent experiments. Error bars represent SEM, t-test, *P < 0.05, **P < 
0.01.   
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3.2.7 XIAP is involved in E6AP-induced dendritic pruning 
If down regulation of XIAP and thus activation of caspase-3 mediates E6AP-
dependent structural remodeling, we predicted that dendritic pruning may be 
prevented by overexpression of XIAP. To this end, we transfected neurons with 
E6AP alone or together with XIAP, and Sholl analysis was performed 24 hrs 
later. We found that while E6AP-transfected neurons had marked dendritic 
pruning, no significant changes in dendritic arborization were detected in cells co-
transfected with E6AP and XIAP WT (Figure 3.12A, 3.12B). In contrast, 
overexpression of an XIAP mutant that was unable to inhibit caspase-9 and 
caspase-3, XIAP D148A/W310A, did not block the E6AP-induced morphological 
changes (Figure 3.12A, 3.12B). Thus, consistent with the role of E6AP-mediated 
ubiquitination and degradation of XIAP, these results strongly indicate a 
reduction in XIAP and its inhibition of caspases as a key step in E6AP-dependent 
dendritic pruning.  
 
3.2.8 The cytoskeletal component tubulin is targeted by caspases in E6AP-
dependent dendritic remodeling  
Having implicated the involvement of caspases in E6AP-dependent dendritic 
remodeling, we wanted to examine potential targets of cleavage by caspase-3 
that would result in a change in neuron morphology. As microtubules are 
essential for structural integrity of dendrites in neurons, we wondered whether 
microtubule components were targeted in the process of E6AP-dependent  
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Figure 3.12 XIAP is involved in E6AP-induced dendritic pruning 
(A) Morphology imaging of primary neurons transfected with surfGFP alone, or 
together with E6AP, E6AP + XIAP WT, or E6AP + XIAP D148A/W310A. Scale 
bar = 50 µm. (B) Sholl analysis showing a blockade of the E6AP effect in 
dendritic pruning by XIAP overexpression; n = 10 cells per condition. Error bars 
represent SEM, t-test, *P < 0.05, **P < 0.01.   
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dendritic pruning. Indeed, studies have shown that the breakdown and 
disassembly of tubulin is involved in both axon and dendrite pruning in 
Drosophila neurons (Watts et al., 2003; Williams and Truman, 2005). In our 
examination of dendritic branches under active pruning, live imaging revealed a 
destabilization, disintegration and retraction from the distal tip of a branch (Figure 
3.7A). To determine whether changes in microtubules occurred during E6AP-
induced pruning, we performed live imaging experiments by live-labeling 
microtubules. We transfected neurons on glass-bottom dishes with surfGFP and 
tet-inducible pTRE-E6AP for 24 hours, and loaded neurons with the microtubule 
dye SiR-Tubulin before inducing E6AP expression with doxycycline. Images of 
the tubulin signal and the overall neuronal structure by surfGFP were captured 
every 20 min for 12 hours (representative images taken at 7 hrs after Dox 
treatment). During the process of dendrite pruning, we found that microtubules 
showed thinning and shrinking at times prior to withdrawal of physical structure of 
a branch, as indicated by the retraction of the red tubulin signal before the green 
surfGFP signal (Figure 3.13A).  
Given that microtubules are the core supporting structure in dendrites, it is 
conceivable that activation of the caspase cascade triggers microtubule 
destruction and structural removal. Indeed, the cleavage of tubulin by caspase-3 
and caspase-6 has been shown to be involved in cytoskeletal degradation during 
axon degeneration (Sokolowski et al., 2014). We therefore wondered whether 
tubulin cleavage occurs in dendrite pruning. In neurons transfected with E6AP,  
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94 
Figure 3.13 Microtubule cleavage and retraction in E6AP-induced dendritic 
remodeling  
(A) Neurons were transfected with surfGFP and pTRE-E6AP for 24 hrs, and 
loaded with SiR-tubulin, a fluorogenic and cell permeable dye for tubulin labeling, 
before being treated with doxycycline (Dox) to induce E6AP expression. Tubulin 
and surfGFP images were obtained every 20 mins for 12 hours following Dox 
application. Representative images show that retraction of microtubule (red) 
(open arrowhead) occurred prior to that of the GFP-positive dendritic branch 
(green) (closed arrowhead). The original position of the dendritic tip is indicated 
by a dashed line. Scale bar = 5 µm. (B) Representative image of E6AP neurons 
immunostained with an antibody specifically against the cleaved microtubule 
(ΔTubulin). Scale bar = 10 µm. (C) Quantification of cleaved tubulin 
immunointensity in neurons transfected with vector control, E6AP, or E6AP + 
Casp3 C163A (E6AP + C3 mutant), compared to control; n = 10. Error bars 
represent SEM, t-test, **P < 0.01.   
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we immunostained with the TubΔCasp6 antibody, which specifically recognizes 
the tubulin sites cleaved by caspase-6 and caspase-3 (Klaiman et al., 2008; 
Sokolowski et al., 2014). Surprisingly, compared to the control, much higher 
levels of cleaved tubulin were detected in E6AP-transfected cells (E6AP 1.7 ± 
0.2, n = 10, p < 0.01) (Figure 3.13B, 3.13C). Upon characterization of the 
localization of the cleaved tubulin signals, we found that the cleaved tubulin was 
increased particularly in minor dendrites, which are those mostly affected by 
E6AP-induced pruning (Figure 3.13B, Figure 3.13C). Interestingly, in cells co-
transfected with E6AP and the caspase-3 mutant C163A, immunostaining signals 
of cleaved tubulin were dramatically reduced (1.2 ± 0.1 over control, n = 10, p > 
0.05) (Figure 3.13C), indicating that the E6AP-dependent tubulin cleavage was 
dependent on caspase-3 activity.  
To further assess the role of tubulin in E6AP-induced dendritic remodeling, 
we overexpressed E6AP along with tubulin. In the presence of higher levels of 
tubulin expression, E6AP-expressing neurons no longer underwent 
morphological changes (Figure 3.14A, 3.14B, 3.14E). Interestingly, when we 
overexpressed a less stable form of tubulin, the acetylation mutant Tubulin K40A, 
along with E6AP, the increase in K40A tubulin failed to block the E6AP-induced 
reduction in dendritic arborization  (Figure 3.14C, 3.14E). These findings indicate 
that the integrity of tubulin or microtubules serves as a key final substrate in 
E6AP-dependent dendritic remodeling. To further examine this idea, we treated 
control and E6AP-expressing neurons with 5 nM taxol to stabilize tubulin. Indeed,  
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Figure 3.14 Tubulin stabilization blocks E6AP-induced dendritic pruning 
(A) Morphology of neurons transfected with surfGFP (Control) or E6AP.  (B) 
Neurons transfected with tubulin WT or E6AP + tubulin WT. (C) Neurons 
transfected with Tubulin K40A, he acetylation mutant of tubulin, or E6AP + 
tubulin K40A. (D) Neurons transfected with surfGFP or E6AP and treated with 
5nM taxol to stabilize microtubules. Scale bar = 50 µm. (E) Quantification of total 
dendritic length; n = 10 cells per condition. Error bars represent SEM, t-test, **P 
< 0.01.   
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we found that treatment with taxol prevented E6AP-induced morphological 
changes (Figure 3.14D, 3.14E). These results support the role of tubulin stability 
as an important determinant in dendritic remodeling caused by E6AP.  
 
3.2.9 E6AP overexpression autism mouse model shows normal neuronal 
density and cortical layer formation  
Abnormal overexpression of E6AP in the brain is directly linked to the 
pathogenesis of autism. We therefore wanted to know whether similar cellular 
regulation and molecular cascades occur in vivo. To this aim, we obtained the 
recently established E6AP autism mouse model. The Ube3A 2X transgenic 
mouse model exhibits a tripling of the normal Ube3A/E6AP gene dosage in 
neurons, replicating idic15 in patients with autism (Smith et al., 2011). The 
increased dosage of E6AP in these mice leads to a recapitulation of the three 
core behavioral autism traits: defective social interaction, impaired 
communication, and increased repetitive behavior.  In addition, recordings in 
hippocampal slices showed reduced strength in synaptic transmission (Smith et 
al., 2011).  
 We first examined the developmental time course of E6AP expression in 
both WT and 2X Tg animals. Hippocampal brain samples were collected from 
P5-P40 mice and subjected to western blotting to measure E6AP protein levels. 
In WT mice, E6AP was expressed at a peak level at P5 and P10, which then 
started declining at P15 until reaching minimal traces at P40. As expected, 2X Tg  
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Figure 3.15 Increased E6AP overexpression in Ube3A 2X Tg mice 
throughout development  
(A) Hippocampal brain lysates were collected from WT or Ube3A 2XTg mice from 
P5 to P40 and E6AP levels were measured by western blot. Tubulin was probed 
as a loading control. (B) Quantification of E6AP western blot intensity; n = 3 
independent experiments. (C) Immunostaining of E6AP in cortical brain slices 
obtained from P15 WT or Ube3A 2X Tg mice. Scale bar = 100 µm. (D) 
Quantification showed an increase in E6AP signal intensity in Tg mice; n = 20 
slices. Error bars represent SEM, t-test, ***P < 0.001.  
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mice showed significantly higher levels of E6AP during the examined 
developmental period (2x Tg - P5: 1.67 ± 0.32 of WT control, p < 0.05; P10: 1.48 
± 0.36, p < 0.05; P15: 1.07 ± 0.29, p < 0.05; P20, 0.85 ± 0.29, p < 0.05; P40, 0.35 
± 0.17, p > 0.05, n = 3 for all time points) (Figure 3.15A, 3.15B). Interestingly, 2X 
Tg mice shared the same time course pattern of E6AP expression (3.15A, 
3.15B). To visualize the E6AP distribution pattern in the cortex, we then 
immunostained E6AP in brain slices of P15 mice. Consistent with westerns, 
E6AP immunointensity in 2X Tg cortical slices was significantly stronger in all 
cortical layers (2.5 ± 0.3 of WT, n = 20 slices, p < 0.001) (Figure 3.15C, 3.15D). 
 To determine the effect of E6AP overexpression on overall brain 
development, P15 brain slices were labeled with nuclear the dye Hoechst to 
indicate structural organization. Examination of the 2X Tg slices revealed normal 
cortical layer pattern, and the thickness of each cortical layer was similar to that 
of the WT animals (Figure 3.16A, 3.16B). Next, we stained P15 slices for the 
neuron specific marker NeuN and found similar distribution and cell density of 
neurons within the cortex (Figure 3.16C, 3.16D). To further examine the effect of 
high E6AP levels on cellular organization, we infected brains at P0 with AAV2 
GFP virus by intraventricular injection, and brain slices were collected at P40 to 
allow sufficient GFP intensity. Infected cortical pyramidal neurons showed regular 
distribution and normal gross cellular structure with the single primary dendrite 
projecting to the pia in both WT and 2X Tg mice (Figure 3.16E). These findings  
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Figure 3.16 Normal cortical layer development in Ube3A 2X Tg mice 
(A) Hoechst staining of brain slices of WT and Ube3A 2X Tg P15 mice. Scale bar 
= 100 µm. (B) Quantification of the thickness of cortical layers I - VI in WT and 2X 
Tg mice; n = 30 slices. (C) Neuronal marker NeuN staining of P15 cortical layers 
from WT or 2X Tg mouse brain slices. Scale bar = 100 µm. (D) Quantification of 
NeuN positive neurons in brain slices; n = 30 slices. (E) GFP AAV2 virus was 
injected into the brain ventricles of WT and Ube3A 2X Tg mice at P0.  Brain 
slices were prepared at P40 and imaged. Scale bar = 100 µm. A portion of layer 
V neurons was enlarged for clarity. Scale bar = 50 µm. Error bars represent 
SEM, t-test.  
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indicate that the increased dosage of E6AP did not cause significant impairments 
in overall neurogenesis and cortical structural development. 
 
3.2.10 XIAP degradation, caspase-3 activation and tubulin cleavage are 
increased in the E6AP autism mouse brain 
In primary cultured neurons, we have shown that E6AP targeted XIAP for 
ubiquitination and degradation. We wondered whether XIAP was also regulated 
in this transgenic autism mouse.  We collected hippocampal brain tissue from 
mice at P15 and examined XIAP protein levels. Indeed, we observed a significant 
decrease in XIAP levels in 2X Tg mice compared to WT control (0.51 ± 0.07 of 
the control, n = 3, p < 0.05) (Figure 3.18A, 3.18B). We also stained slices for 
XIAP to determine the pattern of XIAP decrease among different cortical layers. 
We found that in slices obtained from 2X Tg mice, XIAP immunointensity was 
decreased in all the cortical layers, with the overall intensity reduced to 0.48 ± 
0.33 of the WT control (n = 20 slices, p < 0.001) (Figure 3.17A, 3.17B). Given the 
elevated amount of E6AP in 2X Tg mice, we assumed that changes in XIAP 
resulted from enhancement in protein ubiquitination. In order to determine the 
general ubiquitination levels in the transgenic mouse brain and prevent rapid 
protein degradation, we tried to accumulate ubiquitinated proteins in the mouse 
brains by injecting the proteasomal inhibitor MG132 (10 mM, 1.5 µl in each 
ventricle) into both ventricles (Villamar-Cruz et al., 2006; Wojcik et al., 2015). 
Hippocampal and cortical brain tissues were collected 12 hrs later for western  
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Figure 3.17 XIAP is decreased and ubiquitination is increased in Ube3A 2X 
Tg mice  
(A) XIAP staining in cortical brain slices from P15 WT or Ube3A 2X Tg mice. 
Scale bar = 100 µm. (B) Quantification showed a decrease in XIAP signal 
intensity in 2X Tg mice; n = 20 slices. (C) MG132 (10 mM, 1.5 µl in each 
ventricle) was injected into the brain of both WT and 2X Tg mice at P3 for 12 hrs. 
Brain lysates were probed for ubiquitin signals. An elevated ubiquitination 
amount was detected in 2X Tg mice under MG132 treatment. Error bars 
represent SEM, t-test, *P < 0.05, ***P < 0.001. 
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analysis.  Indeed, in the MG132 treated brain lysates, ubiquitination signals were 
increased in 2X Tg samples (Figure 3.17C).  
  We have shown in cultured neurons that XIAP reduction led to activation 
of the caspase cascade. We wondered whether the same signaling occurred in 
the autism model mouse. We collected hippocampal brain tissue samples from 
mice at P15 and measured the cleaved, i.e. active form, of caspase-3 by 
western. Compared to WT mice, cleaved caspase-3 levels were significantly 
increased in 2X Tg mice (1.4 ± 0.01-fold increase, n = 3, p < 0.01) (Figure 3.18A, 
3.18C), paired with a decrease in caspase-3 levels (Figure 3.18A). Consistent 
with our findings in cultured neurons, we observed that cleaved tubulin levels 
were also increased in the 2X Tg animals (1.4 ± 0.04 of the WT control, n = 3, p 
< 0.01) (Figure 3.18A, 3.18D).  
  
3.2.11 E6AP autism mouse model neurons show impairment in spine 
maturation and reduction in dendritic branching 
In the E6AP transgenic autism animals, we detected molecular and signaling 
regulation similar to that found in E6AP-transfected neurons. We therefore 
wanted to determine whether these molecular changes were accompanied by 
morphological alteration in neurons. Brain slices were prepared from P15 mouse 
brains after Golgi staining, and the spines at the basolateral dendrites were 
measured in layer V pyramidal neurons. Representative spine images and spine 
tracings are shown in Figure 3.19A. Similar to its effects in cultured neurons,  
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Figure 3.18 XIAP degradation, caspase-3 activation and tubulin cleavage 
are increased in the E6AP autism mouse brain 
(A) Brain lysates collected from WT or Ube3A 2X Tg mice at P15 were probed for 
E6AP, XIAP, caspase-3, cleaved caspase-3, cleaved tubulin and total tubulin. 
GAPDH was also probed as a loading control. (B - D) Quantification analysis of 
western blots for XIAP, cleaved caspase-3, and cleaved tubulin; n = 3 for each. 
Error bars represent SEM, t-test, *P < 0.05, **P < 0.01.   
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increased E6AP levels in the mouse brain led to a decrease in spine density 
(WT: 1.7 ± 0.1 spines/µm,; 2X Tg: 1.4 ± 0.1 spines/µm, n = 10 neurons, p < 0.05) 
(Figure 3.19A, 3.19B). Although spine density was decreased, mean spine length 
was increased in 2X Tg neurons (WT: 1.2 ± 0.3 µm/spine; 2X Tg: 1.3 ± 0.3 
µm/spine, n = 10, p < 0.01) (Figure 3.19C). Since we saw an increase in filopodia 
in culture neurons, we wondered whether the increase in spine length suggests a 
similar change in transgenic animal spines. Indeed, both the number and 
percentage of filopodia were increased in 2X Tg mice (for filopodia number, WT: 
1.6 ± 0.4 filopodia/50 µm, 2X Tg: 3.2 ± 0.7 filopodia/50 µm, n = 10, p < 0.05; for 
filopodia percentage, WT: 1.8 ± 1.1%, 2X Tg: 4.4 ± 1.4%, n = 10, p < 0.05) 
(Figure 3.19D, 3.19E). These results suggest that in Ube3A 2X Tg mice, an 
increase in E6AP levels resulted in suppression of spine formation and/or 
maturation, leading to a decrease in spine density and an increase in filopodia.  
 As increased E6AP levels in cultured neurons lead to a reduction in 
dendritic arborization by dendritic pruning, we wanted to determine whether this 
also occurred in the neurons of 2X Tg animals. We subsequently collected brain 
slices at P15 and subjected them to Golgi staining to study morphology of Layer 
V pyramidal neurons. Compared to WT animals, the mean number of dendritic 
branches per cell was significantly decreased in 2X Tg animals (WT: 31 ± 2.9 
dendrites, n = 13; 2X Tg: 18.6 ± 1.4 dendrites, n = 12, p < 0.05) (Figure 3.19F, 
3.19G). Along with fewer dendrites, total dendritic length in neurons was also 
markedly reduced in 2X Tg mice (WT: 1608 ± 187µm, n = 13; 2X Tg: 998 ±  
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Figure 3.19 E6AP autism mouse neurons show impairment in spine 
maturation and reduction in dendritic branching  
(A) At P15, brains of WT and 2X Tg mice were subjected to Golgi staining. 
Representative images of spine morphology of Layer V cortical neurons are 
shown. (B) Mean spine density was decreased in Ube3A 2X Tg mice; n = 10 
neurons. (C) Mean spine length was increased in 2X Tg mice; n = 10 neurons. (D 
and E) The percentage and number of filopodia was increased in 2X Tg mice; n = 
10 neurons. (F) Representative layer V pyramidal neuron tracing images of Golgi 
staining from P15 WT and 2X Tg mouse brain slices. (G and H) Measurement of 
average dendrite number and total dendritic length in pyramidal neurons; n = 12 
neurons. Error bars represent SEM, t-test, *P < 0.05, **P < 0.01.   
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85µm, n = 12, p < 0.05) (Figure 3.19H). These results suggest a defect in 
dendritic development in Ube3A 2X Tg mice as a result of increased 
Ube3A/E6AP expression in the brain. These in vivo findings support the role for 
E6AP in down regulation of dendritic arborization, presumably by dendritic 
pruning mediated by the molecular pathway involving the E6AP-induced 
ubiquitination and degradation of XIAP, the subsequent activation of caspase-3, 
and the resulting cleavage of tubulin and local dendritic degeneration (Figure 
3.20).  
 
3.3 Discussion  
In this study we elucidate for the first time the molecular mechanisms underlying 
E6AP-dependent regulation of dendritic arborization. We show, both in vitro in 
cultured neurons and in vivo in E6AP ASD mice, that increased levels of E6AP 
causes XIAP ubiquitination and degradation, resulting in activation of the 
caspase cascade, which ultimately leads to reduced dendritic arborization via 
tubulin cleavage and dendritic pruning (Figure 3.20). These neurodevelopmental 
deficits and the underlying mechanistic cascades represent the molecular 
pathology of ASD resulting from aberrant up-regulation of E6AP expression.  
Sholl analysis of different DIV time points showed that the reduction in 
arborization was not due to a suppression of growth, indicating active dendrite 
retraction. However, a weakness of that experimental design was that it did not 
allow for comparison between the state of individual neurons before and after  
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Figure 3.20 
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Figure 3.20 Summary of the E6AP-dependent dendritic remodeling pathway 
Diagram depicting the molecular pathway by which E6AP leads to dendritic 
remodeling. Increased E6AP expression leads to an increase in XIAP 
ubiquitination via its function as an E3 ligase. As a result, more XIAP is targeted 
for the proteasome for degradation. The decrease in XIAP causes a reduction in 
the inhibition of caspases, thereby increasing caspase activity. Caspases 
subsequently target microtubules for cleavage and destabilize the dendritic 
cytoskeleton, leading to retraction and fragmentation of the dendritic branch.  
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transfection. To overcome this, we carried out live-imaging experiments using 
Tet-inducible E6AP expression. The live imaging experiments revealed active 
dendritic pruning in E6AP-overexpressing neurons. We observed distal 
fragmentation and thinning of dendritic branches, followed by tip retraction and 
eventual disappearance of dendrites. Similar mechanisms of pruning have been 
observed in Drosophila da sensory neurons (Williams and Truman, 2005). In vivo 
time lapses of remodeling da neurons showed both local degeneration involving 
thinning, severing, and fragmentation of the disrupted dendrite, as well as 
retraction of distal branch tips after severing events (Williams and Truman, 
2005). In line with our finding on the role of E6AP in dendritic remodeling, a study 
of drosophila da neurons has shown that loss of the E6AP homolog dUBE3A 
alters terminal dendritic branching and growth (Lu et al., 2009). In mice, 
knockdown of E6AP in pyramidal neurons disrupts apical dendrites, which is also 
observed in the maternally-deficient Ube3A AS mouse model (Miao et al., 2013).  
We identify XIAP as a novel ubiquitination and degradation target for 
E6AP E3 ligase activity. The role of XIAP has previously been implicated in axon 
degeneration. In the absence of XIAP, dorsal root ganglion (DRG) axons 
subjected to nerve growth factor withdrawal show accelerated degeneration and 
increased caspase-3 activity, along with decreased levels of XIAP (Unsain et al., 
2013). Furthermore, sustaining XIAP levels in degenerating axons reduces 
caspase activation and suppresses axonal degeneration (Unsain et al., 2013). 
More importantly, the degradation of DIAP1, a caspase-antagonizing E3 ligase in 
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drosophila, is necessary for sensory neuron dendrite pruning (Kuo et al., 2006). 
Consistent with those studies, we find that XIAP levels are decreased during 
dendritic pruning, and that the reinstatement of XIAP rescues E6AP-dependent 
pruning.   
There are two possible mechanisms by which XIAP could regulate 
caspase activation in E6AP-dependent dendritic pruning. First, as XIAP inhibits 
both the cleavage of caspase-3 and its access to target substrates (Chai et al., 
2001; Riedl et al., 2001), lowering XIAP levels by E6AP-mediated ubiquitination 
and degradation removes its inhibition on caspases. This would allow caspases 
to be activated and act on their substrates. Second, XIAP can directly target 
caspase-3 for ubiquitination and proteasomal degradation (Schile et al., 2008; 
Suzuki et al., 2001). Our immunostaining and western data demonstrate that 
E6AP-induced XIAP reduction is accompanied with an increase in caspase-3 
cleavage and thus activation, indicating an alleviation of XIAP inhibition in the 
presence of higher levels of E6AP.  
We found caspases to be a key component in the E6AP-dependent 
pruning pathway. In drosophila, the caspase Dronc is responsible for the pruning 
of dendritic arbors in class IV da neurons (Kuo et al., 2006; Williams et al., 
2006b). Caspases have also been shown to play a role in axon pruning of NGF-
dependent DRGs (Cusack et al., 2013; Nikolaev et al., 2009; Simon et al., 2012). 
In cultured hippocampal neurons, local activation of caspase-3 by Mito-KillerRed 
photostimulation was sufficient to induce proteasome-dependent spine 
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elimination and dendrite retraction without cell death (Erturk et al., 2014). In 
agreement with these studies, we demonstrate that the E6AP-induced pruning 
process in neuronal cultures is dependent on caspase-3 cleavage and activity 
indicated by pharmacological inhibition and rescue experiments. However, we 
observed that the distribution of activated caspase-3 is not limited to the dendritic 
arbors or individual branches; rather, strong signals were also detected in the 
soma. Global caspase activation has been shown to cause widespread damage 
leading to apoptosis (Yuan and Yankner, 2000), however, we did not observe cell 
death even 7 days after E6AP transfection (not shown). In addition, in Ube3A 2X 
Tg mice with tripled E6AP amount and increased levels in cleaved caspase-3, 
Hoechst and NeuN staining in cortical slices failed to show any changes in 
neuron number, indicating a lack of neuron apoptosis in the presence of E6AP-
induced caspase activation. In fact, it is well documented that caspases possess 
many non-apoptotic functions, including developmental axon degeneration, stem 
cell differentiation, and neuronal plasticity (Unsain and Barker, 2015).  Possibly, 
in addition to caspase activation, E6AP overexpression also triggers an up-
regulation of pro-survival signaling cascade(s) such as the PI3K-Akt pathway, 
therefore protecting neurons from overall degeneration.  
The cleavage and retraction of microtubules lends an insight into the 
molecular mechanism of E6AP-dependent dendritic pruning. We observed 
retraction of tubulin from the tip of the dendrite, which preceded retraction of the 
neuronal structure itself. However, cleavage of tubulin by caspases was 
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observed on the dendrite at locations more proximal to the cell body rather than 
at the tip, suggesting a link between proximal cleavage of tubulin and distal 
degeneration. It is possible that microtubule cleavage blocks the trafficking of 
molecular cargo to reach the distal ends, leading to degeneration and retraction 
of the distal dendritic fragment. The details of the pruning process in Ube3A 2X 
Tg mice are yet to be studied and understood. 
Importantly, our in vitro findings were validated in the Ube3A-
overexpressing ASD mouse model. The Ube3A 2X Tg mice show typical autistic 
behavioral deficits, including impaired social behavior, as measured by social 
preference tests, decreased communication, measured by vocalizations, and 
increased repetitive behavior, shown by excessive grooming (Smith et al., 2011). 
In these transgenic animals, we measured neuron number and cortical layer 
structure and thickness and found no obvious changes. In postnatal cortical 
neurons, the structural pattern and orientation of the apical dendrites appeared 
normal. These findings indicate relatively normal brain development, including 
neurogenesis and neuron migration. In contrast, detailed analysis revealed 
alterations in spine formation and dendritic branching. 2X Tg neurons showed 
reduced spine density and increased immature filopodia-like spines, suggesting a 
suppression in spinogenesis, stability or maturation. These findings are 
consistent with the electrophysiological changes found in Ube3A 2X Tg mice 
showing a decrease in mEPSC frequency (Smith et al., 2011). Consistent with 
our in vitro studies, 2X Tg mice showed a reduction in dendritic branching in layer 
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V cortical neurons. Strikingly, the same signaling cascades for dendritic pruning 
observed in E6AP-transfected neurons were also utilized in Ube3A 2X Tg mice. 
The animal brains showed decreased XIAP levels, increased caspase-3 
cleavage and enhanced tubulin cleavage, supporting the involvement of these 
key components in E6AP-mediated pruning.  
Aberrant connectivity and thus malfunction of neural circuitry is one of 
the major common developmental changes in ASD (Doll and Broadie, 2014; 
Ebert and Greenberg, 2013). Our findings on ASD-related alterations in dendritic 
remodeling and spine formation during brain development provide mechanistic 
insights at the cellular and molecular levels. We show that E6AP is expressed in 
the brain mainly during early development, and is then reduced to and 
maintained at a minimal level, which is consistent with the fact that E6AP mRNA 
peaks in the mouse brain at a time considered to be a critical period in 
development (Kroon et al., 2013). In the visual cortex of AS mice, E6AP has 
been shown to regulate experience-dependent neuronal development from P10 
to P25 (Kim et al., 2016; Yashiro et al., 2009).  Thus, it is likely that E6AP is 
involved in dendritic remodeling at a specific time window during development. 
Indeed, in an AS model with maternal E6AP deficiency, reinstatement of E6AP 
expression at birth and at 3 weeks of age was able to rescue motor deficits, while 
reinstatement in adults failed to show rescue effects (Silva-Santos et al., 2015). 
As we observed a shared time course in E6AP expression in both WT and 
Ube3A 2X Tg mice, we predict that with the overexpression of E6AP, the 
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developmental pruning window would remain the same, but the extent of pruning 
is increased due to elevated E6AP activity. Future rescue studies on the E6AP 
ASD model will confirm the existence of a critical window, which will provide 
valuable guidance on clinical therapeutics of ASD patients.  
 
 
 
 
 
 
 
 
 
 
 
 
.
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4.1 Summary of findings  
In this study we elucidate for the first time the molecular mechanisms underlying 
UBE3A/E6AP-dependent regulation of dendritic arborization. We show, both in 
vitro in cultured neurons and in vivo in E6AP ASD mice, that increased levels of 
E6AP causes XIAP ubiquitination and degradation, resulting in activation of the 
caspase cascade, which ultimately leads to reduced dendritic arborization via 
tubulin cleavage and dendritic pruning (Figure 3.20). These neurodevelopmental 
deficits and the underlying mechanistic cascades represent the molecular 
pathology of ASD resulting from aberrant up-regulation of E6AP expression.  
 
4.2 Mechanism of dendritic remodeling 
Our work shows that E6AP leads to changes in dendritic arborization followed by 
removal and disappearance of dendrites. Our live imaging revealed that the 
remodeling process occurred via distal thinning and fragmentation of the 
dendrites before disappearance of the arbor (Figure 3.6). Although the pathway 
involving XIAP and caspase-3 is similar to that of Drosophila pruning, the 
mechanism of remodeling is different. In Drosophila dendritic arborization (da) 
neurons, entire dendrites are cut from their start at the soma during 
metamorphosis (Yu and Schuldiner, 2014). However, we did not find any 
proximal cutting sites or severing of dendrites in our live imaging studies, 
suggesting that the mechanism for structural reorganization may be distinct 
between insects and mammals. Moreover, Drosophila neurons lose their entire 
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dendritic tree during the pruning process via local degeneration, with only the cell 
soma and axon remaining before regrowth of adult dendritic trees. In neurons 
undergoing E6AP-dependent dendritic remodeling, we did not observe the 
complete removal of dendritic arbors; rather we observed a drastic reduction in 
dendrites while still leaving at least one major and some minor dendrites intact. In 
the human brain, as experience-dependent remodeling occurs during postnatal 
brain development, it is unlikely that neurons would lose their dendritic tree in its 
entirety, as this could have drastic negative effects on brain circuitry. Instead, 
smaller dynamic changes of dendritic retraction and growth over time result in 
reorganization of neuronal connections, as demonstrated in dentate gyrus 
neurons (Goncalves et al., 2016). Furthermore, the severing of microtubules in 
da neurons involves the severing protein Katanin p60-like 1, which breaks the 
microtubules proximal to the cell soma and initiates dendrite degeneration (Lee 
et al., 2009).  During neuronal differentiation in mammalian neurons, Katanin p60 
has been shown to regulate dendrite retraction by promoting microtubule 
reorganization (Korulu et al., 2013). Whether Katanin p60 is involved in E6AP-
dependent remodeling remains to be investigated. However, we did find that 
microtubules are cleaved by caspases as a result of E6AP-overexpression. 
Cleavage of actin and tubulin by caspases has been shown to be involved in 
axonal degeneration in neuronal development and injury, suggesting that axon 
and dendrite degeneration and remodeling may share similar mechanisms 
(Sokolowski et al., 2014).  
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 Although processes intrinsic to the cell regulate cleavage and 
degeneration, extrinsic processes influence dendritic pruning in Drosophila as 
well. Glial cells have been shown to regulate the site of the initial proximal 
cleavage and subsequent degeneration of the dendrites (Han et al., 2011). 
Interestingly, microglia play a critical role in mammalian synaptic pruning during 
development of the visual system (Schafer et al., 2012). This function is 
dependent on the microglia-specific phagocytic pathway involving the 
complement receptor 3 (CR3) and its ligand C3. CR3 expressed on surface of 
glia recognizes the expression of C3 on synaptic sites as a signal for engulfment 
and removal (Schafer et al., 2012). An interesting future study of E6AP-
dependent dendritic remodeling would be to determine the role of glial cells in the 
remodeling process, and whether the complement system is involved in 
degradation of dendrites. Indeed, it has been shown that mice lacking a 
complement pathway component have increased dendritic branching and 
dendritic spine density, suggesting that the complement pathway and neuron-glia 
interaction are important for proper brain development (Ma et al., 2013).  
 
4.3 Dendrite specificity of E6AP-dependent remodeling  
We have shown that E6AP overexpression leads to a reduction in branch 
number, primarily targeting secondary and tertiary branches, along with smaller 
primary branches and leaving one major primary branch intact (Figure 3.2). 
However, how E6AP targets specific branches while leaving others intact 
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remains to be studied. Specifically, the time course of dendrite retraction and 
removal, and why some branches are retracted before others, is not yet known. 
One possibility is that the distribution or activity of E6AP has site and region 
selectivity in a neuron. A potential experiment is to track the expression of a 
fluorescently tagged E6AP protein in dendrites relative to the pruning pattern of 
the neuron. For example, frequent live imaging of neurons expressing a tet-
inducible E6AP-mCh plasmid could be carried out to observe the increase in the 
mCh signal and the subsequent pruning of a specific dendrite and determine 
whether there is a relationship between the increase in E6AP within a specific 
dendrite and its probability of pruning. If E6AP is specifically increased in some 
dendrites that are destined for pruning and subsequent removal, perhaps the 
area-specific decrease of XIAP also contributes to dendrite specificity. When 
comparing the localized decrease of XIAP levels in hippocampal neurons, we 
found that with E6AP overexpression, XIAP levels were preferentially decreased 
in the minor dendrites and the soma (Figure 3.10), suggesting that localized 
XIAP decrease may lead to dendrite specificity. Furthermore, increased caspase 
cleavage may contribute to dendrite specificity. Additional experiments to 
determine the activity pattern of caspase-3 cleavage could be done using 
Fluorescence Resonance Energy Transfer (FRET), where the interaction 
between a fluorescently-tagged caspase-3 and a fluorescently-tagged synthetic 
caspase target sequence is measured in a real-time manner (Deniz et al., 1999; 
Tyas et al., 2000). This would allow visualizing of the location of increased 
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caspase-3 activity followed by change in morphology. Indeed, local activation of 
caspase-3 by Mito-KillerRed photostimulation was sufficient to induce 
proteasome-dependent spine elimination and dendrite retraction without cell 
death, suggesting that local caspase activation is potential key step in E6AP-
dependent dendritic changed (Erturk et al., 2014).  
 
4.4 E6AP-dependent ubiquitination of XIAP 
We have shown that E6AP targets XIAP for ubiquitination and subsequent 
degradation (Figure 3.9), and have identified XIAP as a novel target for E6AP. 
However, some aspects of this proteasome-dependent regulation remain to be 
investigated. We found that the ubiquitinated XIAP had increased molecular 
weight to as high as 250 kD, indicating a conjugation of a long ubiquitin chain 
(Figure 3.9A). A polyubiquitin chain is formed by a series of conjugations of 
ubiquitin molecules to lysine (K) residues on other ubiquitin units. Studies have 
shown that two types of ubiquitin chains are most commonly used in protein 
ubiquitination, K48 and K63 chains (Metzger et al., 2012). Which type of chain is 
conjugated to XIAP by E6AP remains to be investigated. This could be done by 
performing a ubiquitination assay in HEK cells with HA-tagged mutant ubiquitin 
that has either K48 mutated to R48 or K63 mutated to R63 and observing the 
effect of those mutants on the XIAP polyubiquitination pattern. In addition, we 
have yet to determine which lysine residue of XIAP is targeted for attachment of 
the ubiquitin chain. This could be determined by creating XIAP mutants, where 
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each of the 28 K residue is individually mutated to R, and performing 
ubiquitination assays with HA-tagged ubiquitin. The effect of each XIAP K to R 
mutation on ubiquitination levels will determine which K is targeted by E6AP.  
 
4.5 The role of E6AP-dependent dendritic remodeling in ASDs 
Using transgenic animal tissue, we have shown that E6AP levels regulate 
dendritic development in vivo. In this study, we show that E6AP levels are 
elevated during postnatal development and that increased E6AP levels in mice 
lead to a reduction in dendritic branching and length (Figure 3.14). We believe 
this work elucidates a key role for E6AP in dendritic remodeling, proposing that 
E6AP at endogenous levels regulates postnatal dendritic remodeling, a process 
essential to proper brain development. However, increased levels of E6AP in the 
case of ASDs could lead to heightened E6AP activity and subsequent dendritic 
remodeling, leading to a change in neuronal connections and overall brain 
circuitry. Although we have shown a decrease in dendritic branching in mice as a 
result of E6AP overexpression, we have yet to determine the dendritic growth 
dynamics under these conditions. Significant knowledge could be gained by 
performing in vivo two-photon live imaging of cortical neurons in both WT and 
Ube3A 2X Tg mice by imaging the same neurons on a daily basis and analyzing 
dendritic dynamics. In addition, transgenic mice with inducible E6AP expression 
can be used to determine the time-dependency of the role of E6AP 
overexpression in ASD.  
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 Furthermore, to more strongly implicate the role of E6AP-dependent XIAP 
ubiquitination in the E6AP ASD mouse model, rescue experiments are needed. 
In cultured neurons, we have shown that overexpression of XIAP along with 
E6AP can prevent the E6AP-dependent dendritic reduction (Figure 3.11). This 
experimental approach can be applied to transgenic animals, where injections of 
XIAP virus can be administered to both WT and Ube3A 2X Tg mice to rescue 
changes in dendritic branching. This study can be further elaborated by rescuing 
at various time points to determine if a specific time window is most sensitive for 
E6AP-dependent remodeling and subsequent intervention. Similar studies can 
also be done with down-regulating the expression of E6AP by injection of E6AP 
siRNA to correct for the overexpression in transgenic animals.  
In addition to morphological analysis, the effectiveness of rescuing can be 
measured by behavioral outcome as Ube3A 2X Tg mice show typical autistic 
behavioral deficits, including impaired social behavior, decreased 
communication, and increased repetitive behavior (Smith et al., 2011). The 
extent to which XIAP overexpression or E6AP down-regulation can rescue 
behavioral deficits, along with a correlation of that rescue with the underlying 
morphological changes and effects on dendritic remodeling, will allow us to make 
stronger conclusions about the role of E6AP in dendritic development in the 
context of ASDs.  
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A1.0 Introduction to Appendix 
In addition to my dissertation project on neuronal remodeling by E6AP, I have 
also worked on a second project in the lab. The work in this appendix is on the 
investigation of SCRAPPER, another E3 ubiquitin ligase, as a modulator of 
glutamate receptor expression. I have made significant progress in the 
development of this story and will be completing this study within the upcoming 
months, along with preparation of a manuscript for publication.  
 
A1.1 Abstract 
AMPA receptors (AMPARs) are the primary mediator of interneuronal 
communication and play a crucial role in higher brain functions, including learning 
and memory. The molecular processes that regulate AMPAR synthesis and 
turnover, however, are poorly understood. Our previous work demonstrated that 
AMPARs are subject to ubiquitination by the E3 ligase Nedd4, which results in 
receptor internalization and proteasome-mediated degradation. Here, we study 
the role of the recently identified E3 ligase SCRAPPER in regulating AMPAR 
levels. We find that SCRAPPER (SCR) reduces GluA1 levels both in primary rat 
cultured neurons and HEK293A cells and colocalizes with GluA1 in neurons. 
Although SCRAPPER is an E3 ligase, its effect on GluA1 does not seem to be 
dependent on proteasomal degradation, as it does not increase the ubiquitination 
of GluA1. The half-life of GluA1 is not affected by SCRAPPER and blocking 
proteasomal and lysosomal function does not alter GluA1 reduction. We find, 
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however, that SCRAPPER may be decreasing GluA1 levels by affecting the 
translation machinery, mainly targeting eIF4G and reducing its levels, therefore 
affecting total GluA1 synthesis rates. This study provides a novel mechanism for 
glutamate receptor trafficking and regulation, and suggests that SCRAPPER 
specifically regulates AMPAR levels by targeting cellular translation machinery. 
 
A1.2 Introduction 
α-Amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid receptors (AMPARs) are 
heterotetrameric glutamate-gated ion channels that mediate the majority of 
excitation synaptic transmission in the brain. Regulation of AMPARS at the 
synapse is an important molecular mechanism underlying synaptic plasticity, a 
process involved in learning and memory (Malinow and Malenka, 2002). The 
trafficking of AMPARs is essential to the process of long-term potentiation and 
depression, both have which have been implicated in neurodevelopmental and 
neurodegenerative disorders. (Huganir and Nicoll, 2013). The amount of 
functional AMPARs on the cell surface can be altered by trafficking via vesicle-
mediated membrane insertion, internalization, and recycling, as well as altered 
rates of synthesis and degradation (Malinow and Malenka, 2002). 
One specific modification on receptors and proteins that can alter their 
trafficking is ubiquitination. Ubiquitin is a small 76-amino acid protein that can be 
covalently conjugated to other proteins by the process of ubiquitination. This 
process involves catalyzed reactions by three enzymes: E1, E2, and E3 ligases. 
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The ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-dependent 
manner, E2 conjugates the ubiquitin molecule to the E3 ligase, and E3 is the 
ligase that links ubiquitin to its substrate at lysine residues and determines 
substrate specificity.  Once a single ubiquitin is conjugated to the target protein 
(monoubiquitination), a lysine residue within ubiquitin itself can be linked to a 
second ubiquitin and so on to form a ubiquitin chain (polyubiquitination).  A 
ubiquitin chain conjugated to a protein functions as a tag that can be recognized 
and sorted to the proteasome or lysosome for degradation. Monoubiquitination of 
proteins can regulate processes such as membrane transport and transcriptional 
regulation, while polyubiquitination often results in sorting to the proteasome or 
lysosome for degradation (Hicke, 2001; Nandi et al., 2006). Furthermore, 
ubiquitin moieties can be removed from their target proteins by protein-specific 
deubiquitination enzymes (DUBs). The ubiquitin-proteasome system (UPS) plays 
an important role in cell growth, neurite extension, structural remodeling, and 
synaptic formation and plasticity (d'Azzo et al., 2005; Hurley et al., 2006; Nandi et 
al., 2006; Segref and Hoppe, 2009; Shearwin-Whyatt et al., 2006). Dysfunction of 
the UPS is involved in global neurodegeneration in neurodegenerative diseases 
including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis (Dawson, 2006; Lehman, 2009; Sakamoto, 2002; Whatley et al., 2008). 
As the trafficking of AMPARs is important for essential brain functions, it is 
important to find E3 ligases that modulate levels of AMPARs at the synapse. Our 
lab and others have shown that AMPARs are subject to ubiquitination by the E3 
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ligases Nedd4, RNF167, and APCCdh1, leading to a reduction in cell-surface 
receptor expression and decreased synaptic transmission (Fu et al., 2011; Lin et 
al., 2011; Lussier et al., 2012). Our lab has also identified USP46 as a specific 
DUB for AMPARs; USP46 reduces ubiquitination and degradation of AMPARs 
and increases its synaptic accumulation (Huo et al., 2015). Additionally, others 
have also shown that all subunits of AMPARs can be ubiquitinated in an activity-
dependent manner (Widagdo et al., 2015). 
As important as modifications on receptors that lead to their internalization 
and recycling is the synthesis of receptors and factors that regulate translation. In 
eukaryotes, protein translation requires recruiting the ribosome to the mRNA, 
which involves proper assembly of the eukaryotic initiation factor 4F (eIF4F) 
complex. This complex is made up of the cap-binding protein eIF4E, eIF4A, and 
the scaffolding protein eIF4G, which altogether link the mRNA to the ribosome 
(Sonenberg and Hinnebusch, 2009). Translation initiation is regulated by eIF4E-
binding proteins (4E-BPs) that repress translation by sequestering eIF4E, thus 
preventing formation of the eIF4F complex and inhibiting ribosome and mRNA 
association (Sonenberg and Hinnebusch, 2009). Specifically, 4E-BP2 has been 
shown to be critical for hippocampal synaptic plasticity and memory formation 
(Banko et al., 2005). More importantly, deletion of 4E-BP2 leads to selective 
upregulation of glutamate receptor subunits GluA1 and GluA2 synthesis, 
facilitating AMPAR-mediated synaptic transmission, suggesting that specific 
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components of the eIF4F complex may mediate the translation of some proteins 
without affecting others (Ran et al., 2013).  
SCRAPPER (SCR) is an E3 ubiquitin ligase found in mammalian 
synapses that regulates synaptic transmission (Yao et al., 2007). At the synapse, 
SCR ubiquitinates the active zone protein Rab3-interacting molecule 1 (RIM1), 
which is a Ca2+-dependent synaptic vesicle priming factor in the active zone that 
is required for synaptic plasticity (Sudhof, 2004; Wang et al., 1997; Yao et al., 
2007).  Additionally, SCR+/- mice display learning and memory deficits in fear 
acquisition and contextual fear memory tests (Yao et al., 2011).  
Considering that glutamate receptor trafficking is important in learning and 
memory, and that SCR regulates these processes, we examined whether SCR 
affects glutamate receptor trafficking via its function as an E3 ligase. We found 
that SCR decreases levels of GuA1 in hippocampal neurons and HEK cells. To 
our surprise, however, SCR did not increase ubiquitination levels of GluA1, 
suggesting that GluA1 levels were not altered by direct ubiquitination and 
degradation. Rather, we found that SCR modulates levels of the cellular 
translation machinery components eIF4E/eIF4G, and that disruption of this 
complex leads to a reduction in GluA1 levels. These findings suggest a novel 
pathway by which glutamate receptor levels are altered by SCR. 
  
136 
A1.3 Results  
A1.3.1 SCRAPPER overexpression decreases GluA1 levels in neurons 
To examine the interactions between the AMPAR subunit GluA1 and 
SCRAPPER (SCR), we first wanted to determine whether the two proteins co-
localize in neurons. Hippocampal neurons at approximately two weeks of age in 
culture (DIV15) were co-immunostained with specific antibodies against SCR and 
GluA1 (experiment performed by Natalie Tukan). GluA1 was distributed in a 
punctate manner in spine protrusions (Figure A.1A). Although the distribution 
pattern of SCR was diffuse throughout the neurons, the localization of SCR was 
found to overlap that of GluA1 at various punctate spots (Figure 4.1, white 
arrows). These stainings suggest that GluA1 and SCR are found to be localized 
together in spines.  
 We next wanted to determine whether SCR modulates levels of GluA1. 
We transfected hippocampal neurons at DIV12 with GFP or SCR-GFP, fixed 
them 3 days later, and immunostained for total GluA1 using an antibody targeted 
to the C-terminus of the receptor subunit (Figure A.1B). Strikingly, we found that 
overexpression of SCR caused a 33% decrease in GluA1 expression levels in 
culture neurons (Figure A.1B, A.1C). To confirm this effect, we also transfected 
HEK239A cells with GluA1-GFP and either GFP or SCR-GFP for 48 hrs and 
collected the samples for western blotting. Levels of GluA1 were drastically 
reduced with the overexpression of SCR compared to GFP control cells (Figure 
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A.1D). These results suggest that SCR regulates and decreases levels of GluA1 
in neurons.  
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Figure A.1 
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Figure A.1. SCRAPPER overexpression decreases GluA1 levels in neurons 
(A) Primary rat hippocampal neuron cultures were stained for GluA1 and 
SCRAPPER by immunocytochemistry at DIV15. Arrows show overlap of GluA1 
and SCR signal. (B) Neurons were transfected with GFP or SCR-GFP at DIV12 
and fixed 3 days later. Neurons were stained for total GluA1 with a GluA1C 
antibody. (C) GluA1 puncta were quantified in neurons; n = 10 neurons per 
condition. (D) HEK293 cells were co-transfected with GluA1-GFP and either a 
control vector or SCR-GFP.  Two days after transfected, cells were lysed, 
collected, and subjected to western blotting for probing with GluA1, SCR, and 
tubulin antibodies. (E) Quantification of western blot signals in HEK cells; n = 3 
independent experiments. Data represent mean ± SEM, t-test, *P<0.05, 
**P<0.01.  
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A1.3.2 SCRAPPER decreases GluA1 in a ubiquitination-independent 
manner  
The ubiquitination process of a protein involved the conjugation of ubiquitin 
molecules from an E3 ligase to its target substrate, resulting in the addition of a 
polyubiquitin chain on the target protein. Previously, we identified Nedd4 as an 
E3 ligase for GluA1 (Lin et al., 2011; Zhang et al., 2009). To further investigate 
the mechanism by which SCR alters GluA1 levels, we wanted to determine 
whether ubiquitination of GluA1 was altered in the presence of SCR. To this end, 
we transfected HEK cells with GFP-GluA1 alone or together with SCR. Forty-
eight hours later, GluA1 was immunoprecipitated with a GluA1-specific antibody 
and immunocomplexes were probed for HA-ubiquitin. In the absence of 
transfected ubiquitin, ubiquitination of GluA1 was not increased with 
overexpression of SCR (Figure A.2A, lanes 1 and 2). Since ubiquitination could 
be inefficient in heterologous cells, we transfected cells with HA-ubiquitin to 
enhance ubiquitination. To our surprise, GluA1 ubiquitination was not increased 
even with transfection of ubiquitin (Figure A.2A, third lane, Figure A.2B). As a 
positive control, we transfected GluA1 with Nedd4 with and without HA-ubiquitin, 
as Nedd4 is a known E3 ligase for GluA1. Indeed, GluA1 ubiquitination was 
significantly increased with Nedd4 and ubiquitin (Figure A.2A, lanes 4 and 5, 
Figure A.2B).  
 We wanted to further investigate how SCR decreases GluA1 levels 
without increasing its ubiquitination, and wanted to confirm its ubiquitination-  
  
141 
Figure A.2  
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Figure A.2. SCRAPPER decreases GluA1 in a ubiquitination-independent 
manner 
(A) GluA1 Ubiquitination assay in HEK293 cells. Cells were co-transfected with 
HA-tagged ubiquitin, GluA1-GFP, and either vector control, SCRAPPER, or 
Nedd4. Lysates were collected two days later, GluA1 was pulled down with a 
specific antibody, and HA-ubiquitin was probed by western blot. GluA1 and 
tubulin were also probed with respective antibodies. (B) HA-ubiquitin levels were 
quantified using ImageJ and normalized to tubulin and then control. SCRAPPER 
does not increase ubiquitination of GluA1; n = 3 independent experiments. (C) 
HEK293 cells were transfected with GluA1 WT-GFP or GluA1-4KR GFP, along 
with either a control vector or SCRAPPER. Cell lysates were collected 48 hours 
after transfection and cells were subjected to western blotting. A GFP antibody 
was used to probe both GluA1 and SCR, and tubulin was probed as a loading 
control. (D) Protein levels were quantified using ImageJ; n = 3 independent 
experiments. Mutating the ubiquitination sites on GluA1 does not change its 
SCR-mediated reduction, suggesting that SCR does not ubiquitinate GluA1. Data 
represent mean ± SEM, t-test, *P<0.05  
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independent effect by several methods. We therefore utilized a GluA1 construct 
in which all 4 lysine residues in the C-terminal have been mutated to arginine 
(GluA1 4KR), preventing the attachment of ubiquitin. Specifically, lysine residues 
at 813, 819, 822, and 868 are mutated to arginine, and we have previously 
shown that Nedd-mediated ubiquitination occurs at lysine residue 868 (Lin et al., 
2011). We transfected HEK cells with GluA1 WT or GluA1 4KR, with or without 
SCR. As initially observed, GluA1 WT levels were decreased with SCR 
overexpression (Figure A.2C and A.2D). However, GluA1 4KR levels were also 
decreased with SCR, suggesting that the mutation of lysine residues not affect 
the SCR-mediated GluA1 decrease, and further supporting a ubiquitination-
independent role of SCR on GluA1 levels.  
 
A1.3.3 SCRAPPER lowers GluA1 levels in a degradation-independent 
manner  
 Although the effect of SCR on GluA1 was not mediated by ubiquitination, 
we wanted to determine whether degradation of GluA1 is involved. We 
transfected HEK cells with GluA1 and HA-Ub alone or together SCR, and treated 
them with the degradation inhibitors MG132 or Leupeptin (LEP). MG132 works 
by inhibiting proteasome-mediated degradation, whereas LEP inhibits lysosome-
mediated degradation. Thirty-six hours after transfection, cells were treated with 
the inhibitors for 12 hours before collecting for a GluA1 ubiquitination assay. 
Under MG132 treatment conditions, SCR-transfected cells did not have higher  
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Figure A.3  
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Figure A.3. GluA1 degradation is not affected by SCR overexpression  
(A) HEK293 cells were co-transfected with HA-ubiquitin, GluA1-GFP, and either 
vector control or SCRAPPER. Twenty-four hours after transfection, cells were 
treated with 10µM of the proteasome inhibitor MG132 or 10µM of the lysosomal 
inhibitor Leupeptin. Cells were lysed and collected 24 hours after treatment and a 
ubiquitination assay was performed on GluA1. (B) Quantification of WB signals; n 
= 3. Blocking proteasome or lysosome function does not alter ubiquitination 
levels on GluA1 by SCR, further supporting that SCR does not decrease GluA1 
levels by targeting it for ubiquitination. (C) HEK293 cells were transfected with 
GluA1-GFP and either a control vector or SCR. Two days after transfection, cells 
were treated with 10µg/ml of the protein synthesis inhibitor cycloheximide for 
various times to observe protein half-life. Cells were then collected and subjected 
to western blotting. (D) GluA1 levels were measured in the absence or presence 
of SCR; n = 3. Data represent mean ± SEM, t-test, *P<0.05, **P<0.01.  
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levels of GluA1 ubiquitination compared to both untreated SCR-transfected cells 
and MG132-treated cells with GluA1 alone (Figure A.3A, lanes 3-5, Figure A.3B). 
Furthermore, levels of total GluA1 were still decreased in SCR-transfected cells 
with MG132 treatment, signifying that the SCR-mediated decrease is not 
mediated by proteasomal degradation. Similarly to MG132, cells treated with LEP 
did not have altered total GluA1 levels or GluA1 ubiquitination (Figure A.3A, 
lanes 5 and 6, Figure A.3B), suggested that SCR does not regulate GluA1 levels 
by increasing its lysosomal degradation.   
 To further study the degradation of GluA1 under conditions of increased 
SCR, we wanted to determine if and how SCR affects the degradation rate of 
GluA1. To this end, we transfected HEK cells with GluA1 alone, or together with 
SCR. Forty-eights hours later, cells were treated with the protein synthesis 
inhibitor cycloheximide (CHX) for various time points. Western blots showed that 
the GluA1 rate of degradation was similar with and without SCR transfection 
(Figure A.3C, A.3D). These findings further confirm that degradation of GluA1 is 
not affected by SCR and that GluA1 levels are altered by SCR in a ubiquitination, 
degradation, and proteasome-independent manner.  
 
A1.3.4 SCRAPPER regulates GluA1 levels by targeting translation 
machinery components  
Overall protein levels are regulated not only by protein degradation, but also by 
protein synthesis. As we found that SCR-mediated effects on GluA1 were not 
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occurring via protein degradation, we wondered whether SCR was affected any 
components of the protein synthesis machinery. It was previously shown that 4E-
BP2, a component of the eIF4F translation initiation complex, is involved in 
regulating levels of GluA1 (Ran et al., 2013). We therefore measured levels of 
translation machinery components in neurons overexpressing SCR. Specifically, 
we measured levels of eIF4E and eIF4G by immunostaining neurons transfected 
with either GFP or SCR-GFP for 3 days (Figure A.4A, A.4C). Interestingly, 
Increased SCR levels did not change levels of eIF4E, but levels of eIF4G were 
significantly reduced (Figure A.4B, A.4D). To confirm this effect, we also 
measured levels of eIF4E and eIF4G in HEK cells by western blot. Although 
levels of eIF4E were slightly reduced with SCR overexpression, eIF4G levels 
were drastically reduced (Figure A.4E, A.4F).  
 As SCR lead to decreased levels of eIF4G, we wanted to determine 
whether disruption of the translation machinery could affect GluA1 levels. We 
treated DIV15 cortical neurons in culture with a specific inhibitor that binds to 
eIF4E and inhibits the formation of the eIF4E/eIF4G complex. Sixteen hours after 
treatment, neurons were collected and GluA1 levels were examined by western 
blotting. Strikingly, inhibiting the eIF4E/eIF4G complex caused a decrease in 
GluA1 levels in a dose-dependent manner (Figure 4.4G). These findings suggest 
that specifically inhibiting the eIF4E/eIF4G translation machinery components, 
GluA1 protein levels are affected. Combined together with the decrease of eIF4G 
mediated by SCR, these data suggest that SCR overexpression leads to a 
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decrease in GluA1 levels via the SCR-mediated regulation of translation 
machinery components.  
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Figure A.4  
 
  
150 
Figure A.4. SCR decreases levels of cellular translation machinery 
components 
(A) Primary rat hippocampal neurons were transfected at DIV12 with either GFP 
or SCRAPPER-GFP. Cells were fixed three days later and stained for eIF4E. (B) 
Staining intensity of eIF4E was quantified using ImageJ; n = 10 cells. (C) 
Neurons were also stained for eIF4G. (D) Staining intensity of eIF4G was 
quantified using ImageJ; n = 10 cells. (E) HEK293A cells were transfected with 
either a control plasmid or SCRAPPER. Two days after transfection, cells were 
lysed and collected and protein levels were analyzed by western blot for eIF4E, 
eIF4G, SCRAPPER, and tubulin as a loading control. (F) Primary rat cortical 
neurons were treated with 50 or 100µM of a eIF4E-eIF4G interaction inhibitor 
(Calbiochem) for 16 hours. Cells were collected and subjected to Western 
blotting. Membranes were probed for GluA1 levels and tubulin. Data represent 
mean ± SEM, t-test, *P<0.05.  
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A1.4 Discussion and future studies  
In this study, we identify a novel pathway by which an E3 ligase can 
modify levels of glutamate receptors. We found that the E3 ligase SCR 
decreases levels of GluA1 in both hippocampal neurons and HEK cells, but that 
this decrease was not mediated by direct ubiquitination of GluA1. We show that 
SCR does not increase ubiquitination of GluA1, GluA1 levels with SCR 
overexpression are not affected by blocking proteasomal or lysosomal 
degradation, and SCR does not later GluA1 degradation rates. Rather, SCR 
targets mRNA translation machinery components and indirectly changes GluA1 
levels.  
Ubiquitination of the translation initiation complex components have been 
previously shown. Specifically, eIF4E ubiquitination has been shown to be 
increased under conditions of cellular stress, occurring at lysine residue K159, 
and possibly mediated by the E3 ligase Chip (Murata and Shimotohno, 2006). 
Interestingly, although ubiquitinated eIF4E retained its ability to bind the mRNA 
cap structure, it no longer had the ability to bind eIF4G (Murata and Shimotohno, 
2006). Modifications have also been found on eIF4G. Specifically, under 
conditions of stress and cytoplasmic stress-granule formation, eIF4G 
sumoylation is increased, a post-translation process that can alter protein-protein 
interactions, protein localization, and protein degradation (Hay, 2005; 
Jongjitwimol et al., 2014). Importantly, sumoylation of eIF4G was found to occur 
at lysine residues K1368, which is located at the eIF4A-binding site, suggesting 
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that modifications of eIF4G at lysine residues can prevent its binding to other 
partners of the initiation complex (Jongjitwimol et al., 2014). Therefore, it is 
possible that SCR-mediated ubiquitination of eIF4G can prevent its assembly into 
the initiation complex and consequently alter levels of GluA1 by inhibiting its 
synthesis. However, it remains to be studied whether ubiquitination of eIF4G 
itself is increased under conditions of increased SCR expression. Future studies 
to determine this include ubiquitination assays of both eIF4E and eF4G with SCR 
overexpression, along with Co-IP assays to examine whether the ubiquitination 
of either protein can lead to decreased binding between them and affect the 
association of the translation machinery complex.  
The effects of SCR on GluA1 levels also need to be further elucidated. As 
GluA1 exerts its effects at the postsynaptic membrane, we need to determine 
whether AMPARs are internalized due to SCR overexpression or whether SCR 
decreases AMPAR trafficking to the membrane by preventing further synthesis of 
receptors. We expect that, as SCR target translation machinery, synthesis of 
GLuA1 is reduced and therefore the insertion of new AMPARs at the surface will 
be decreased. As a control, we also need to examine whether GluA1 mRNA 
levels are altered, although we expect that mRNA levels will remain unchanged. 
However, specificity for GluA1 needs to be determined. To show specificity, we 
need to determine the levels of other postsynaptic proteins (PSD95 and NMDAR 
subunits) by western blot in neurons infected with SCR virus, and also measure 
the mRNA levels of those proteins to see whether any of those are altered.  
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The physiological consequences of reduced AMPAR synthesis by SCR 
also need to be determined. Specifically, AMPA-mediated mEPSCs need to be 
measured under conditions of SCR overexpression. As Nedd4-mediated AMPA 
ubiquitination decreased mEPSC amplitude, but not frequency, and USP46-
mediated deubiquitination increased mEPSC amplitude, we expect that cells with 
reduced AMPA synthesis would also exhibit decreased mEPSCs (Huo et al., 
2015; Lin et al., 2011). Consistent with this hypothesis, the downregulation of 4E-
BP2, which negatively regulates activity of the initiation complex and increases 
GluA1 levels, leads to an increase in AMPA-mediated mEPSC amplitude (Ran et 
al., 2013).  
Another aspect of SCR-mediated altered GluA1 levels that needs to be 
examined is how the localization of SCR mediates its effects. We have shown 
that SCR co-localizes with GluA1 in some instances, although SCR was 
previously shown to be localized to the presynaptic site (Yao et al., 2007). It is 
unlikely that SCR is mediating the effects on postsynaptic GluA1 by its 
localization at the presynaptic bouton, since we have shown that SCR-
transfected neurons have lower GluA1 levels themselves, and as neurons in 
culture are sparsely transfected, the surrounding neurons do not have increased 
SCR levels, suggesting that SCR mediates GluA1 levels within the transfected 
neuron. Further experiments need to be carried out to determine whether SCR 
localizes with the translation machinery components, and whether SCR binds to 
either eIF4E or eIF4G.  
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Although more studies are needed to elucidate the mechanism by which 
SCR mediates GluA1, we have shown so far that its effects are not mediated by 
direct ubiquitination of GluA1. Furthermore, we have shown that SCR decreases 
levels of the translation initiation complex component eIF4G, and that disruption 
of the eIF4E-eIF4G interaction leads to a decrease in GluA1 levels in neurons. 
By showing that SCR mediates GluA1 levels by targeting the translation 
machinery, we provide a novel mechanism by which an E3 ligase can alter 
GluA1 levels and potentially affect excitatory transmission.  
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